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 Hydrogen sulfide (H2S) is the third eukaryotic gaseous signaling molecule that evokes a 
broad range of physiological effects. H2S levels are governed by the rates of both production and 
clearance. In eukaryotes, sulfide clearance occurs primarily via the mitochondrial sulfide 
oxidation pathway which consists of the enzymes sulfide: quinone oxidoreductase (SQR), 
persulfide dioxygenase (PDO), rhodanese and sulfite oxidase. Mutations in PDO result in 
ethylmalonic encephalopathy (EE), an autosomal recessive disorder. There are over 20 mutations 
described in patients with EE. Patients with EE and PDO knockout mice exhibit increased 
excretion of thiosulfate bringing into question the organization of the sulfur oxidation pathway.  
 Kinetic characterization of several EE patient mutations reported in human PDO: L55P, 
T136A, C161Y and R163W, was performed to determine the biochemical penalties incurred by 
these mutations. The variants displayed increasingly impacted kcat/Km values of 18-, 42-, 65- and 
200-fold lower kcat/Km values for R163W, L55P, C161Y and T136A respectively. Similarly, 
T136A, R163W, C161Y and L55P displayed 1.4-, 3-, 11- and 10.5-fold lower iron content 
compared to wild-type PDO, respectively. The PDO mutants all display altered thermal 
stabilities with R16W, L55P, T136A and C161Y displaying 1.2-, 1.4-, 1.4- and 1.7-fold lower Tm 
values compared to wild-type PDO.   
 Recently, bacterial proteins that are fusions between PDO and rhodanese have been 
identified. Existence of such a fusion suggests that their mitochondrial counterparts in higher 
organisms may interact and that characterization of such fusion proteins will facilitate the 
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modeling of interactions between human mitochondrial PDO and rhodanese and aid in 
elucidating the metabolic intermediates in the sulfide oxidation pathway. We have characterized 
a bacterial PDO/rhodanese fusion protein from Burkholderia phytofirmans which displays 1.8-
fold higher PDO activity and 4.8-fold lower Km for GSSH as compared to human PDO, and 
rhodanese activity comparable to other bacterial rhodaneses. Additionally, the rhodanese domain 
catalyzed the formation of GSSH and sulfite from thiosulfate and glutathione, but no detectable 
sulfur transfer activity was observed for the reverse reaction. Similar observation were made for 
the stand-alone rhodanese domain; however, several fold increases in Vmax and Km values for 
thiosulfate and glutathione were observed for the various sulfur transfer reactions, suggesting 
that the PDO domain modulates the activity of the rhodanese domain. Combined, these results 
suggest that the fusion is poised to produce sulfite as its main product. To obtain structural 
insights into its mechanism, crystal structures of wild-type and the sulfurtransferase inactivating 
C314S mutation with and without GSH bound were determined at 1.8, 2.4, and 2.7 Å resolution, 
respectively. The structures revealed that the two active sites are distant and there is no evidence 
of direct communication between them. Bioinformatic analysis displays that this enzyme may be 
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1. 1 Introduction to Sulfide Metabolism  
 Long known as a toxic gas, sulfide like cyanide, targets cellular respiration by reversible 
inhibition of cytochrome c oxidase. The cell has therefore evolved strategies for handling the 
twin challenges of averting toxicity problems while exploiting the signaling potential of 
hydrogen sulfide (H2S), which elicits profound physiological effects (1). Hence, a “safe” window 
must exist within which low intracellular concentrations of H2S are maintained and allowed to 
transiently spike to allow passage of a signal. The concentration width of this window could span 
three orders of magnitude since steady-state intracellular concentrations of H2S are estimated to 
be in the 15-30 nM range, (2,3) while mammalian mitochondrial ATP production is abolished at 
50 µM H2S (4). The steady-state concentrations of H2S are a product of both the metabolic flux 
through the sulfide biogenesis and sulfide oxidation pathways (3) (Fig. 1.1). Three enzymes in 
the mammalian sulfur metabolic network catalyze H2S biogenesis (5,6). Two of these enzymes 
reside in the cytosolic transsulfuration pathway and are cystathionine β-synthase (CBS) and γ-
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cystathionase (CSE). Both of these enzymes are versatile and catalyze H2S production in a 
variety of reactions starting from cysteine and/or homocysteine (7-9). The third enzyme, 
mercaptopyruvate sulfur transferase (MST) (10,11), is both cytosolic and mitochondrial in 
location and transfers the sulfur atom from mercaptopyruvate to an acceptor from where it can be 
subsequently released as H2S. MST works in conjunction with the PLP-dependent enzyme, 
aspartate/cysteine aminotransferase (CAT), which catalyzes the conversion of cysteine to 3-
mercaptopyruvate. Recently, D-amino acid oxidase has been reported to convert to D-cysteine to 
3-mercaptopyruvate, providing an alternative supply route for the MST substrate, 3-
mercaptopyruvate  (12).  
 Sulfide catabolism occurs in the mitochondria and connects sulfur metabolism to the 
electron transfer chain, thereby linking sulfide oxidation to both ATP and reactive oxygen 
species production (Fig. 1.1). Half maximal inhibition of cytochrome c oxidase in cell extracts 
occurs at concentrations of ~0.3 µM versus ~20 µM H2S needed to inhibit cellular respiration in 
intact cells (4). To avoid intracellular sulfide build-up and consequent toxicity, the sulfide 
oxidation pathway is activated at considerably lower (~10-20 nM) sulfide concentrations (4). 
The high sensitivity of the sulfide oxidation pathway to H2S, suggests that the duration of H2S-
based signaling is likely to be short (4). Sulfate and thiosulfate are the major products of the 
mammalian mitochondrial sulfide oxidation pathway, which comprises four enzymes: sulfide 
quinone oxidoreductase (SQR), a persulfide dioxygenase (PDO) that is the product of the ethe1 
gene, rhodanese, and sulfite oxidase (13). This chapter focuses on the structural enzymology and 




Figure 1.1. Scheme showing pathways of biogenesis and catabolism of H2S. DAO is D-amino 
acid oxidase.  
 
 
1.2 Enzymology of H2S Biogenesis  
1.2.1 Cystathionine β-synthase  
1.2.1.1 Structural Organization of CBS 
 CBS is a multidomainal protein which, in its role in the transsulfuration pathway, 
catalyzes the condensation of homocysteine and serine to produce cystathionine (14). 
Homocysteine is a redox-active nonprotein amino acid that is produced by hydrolysis of S-
adenosylhomocysteine, a product of S-adenosylmethionine (AdoMet)-dependent methylation 
reactions. Homocysteine is either recycled in the methionine cycle via the action of methionine 
synthase or committed to cysteine synthesis by the action of CBS (Fig. 1.1). Mutations in CBS 
are the most common cause of homocystinuria, an autosomal recessive disorder, characterized by 
severely elevated plasma homocysteine levels (15). CBS deficiency affects multiple organ 
systems including the ocular, skeletal, cardiovascular and the central nervous system (16).  
In addition to the canonical transsulfuration reaction, CBS catalyzes H2S-producing reactions in 
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which serine is substituted by cysteine (7,9). These reactions involve β-replacement of cysteine 
by homocysteine, cysteine or water to generate cystathionine, lanthionine or serine, respectively 
in addition to the common product, H2S.  
 CBS is a homodimeric enzyme. The full-length human enzyme is prone to aggregation 
and exists in multiple oligomeric states ranging from 2-to 16-mers (17). The predominance of the 
4-mer in the aggregated mixture has led to confusion in the literature about CBS being a 
homotetramer. Each monomer is organized into an N-terminal heme-binding domain, a central 
PLP-binding catalytic core and a C-terminal AdoMet-binding regulatory domain, which contains 
a tandem repeat of CBS domains. The latter, named after this protein, is found in all three 
domains of life and refers to a β−α−β−β−α secondary structure motif often associated with 
energy sensing that binds ATP or AMP (18)(19). In CBS, it binds the allosteric activator, 
AdoMet, which renders transsulfuration flux sensitive to cellular methyl donor status. Thus, 
when AdoMet levels are low, sulfur is spared and utilized via the methionine cycle to support 
AdoMet synthesis. In contrast, when AdoMet levels are plentiful, sulfur metabolism is directed 
towards cysteine synthesis via activation of CBS.  
 The crystal structures of full-length CBS from Drosophila melanogaster (dCBS, Fig. 
1.2A) and a truncated variant of human CBS (hCBS) which lacks the C-terminal regulatory 
domain have been reported (19-21)(20-22). The N-terminal heme domain spans residues 1-70 in 
hCBS and 1-45 in dCBS while the middle PLP domain spans residues 71-411 in hCBS and 46-
350 in dCBS. A 27 residue-long linker (351–377) visible in the structure of dCBS connects the 
PLP and C-terminal domains, which based on sequence alignment, is predicted to extend 




Figure 1.2. Structure and catalytic mechanism of CBS. (a) Structures of full-length dCBS. 
The protein comprises an N-terminal heme-binding domain (red), a PLP domain (blue) and a C-
terminal AdoMet-binding domain (yellow). A linker (grey) connects the PLP-and C-terminal 
domains. (b) Close-up of the active site of hCBS. Hydrogen bonds between PLP and amino acids 
lining the active site are shown as dotted lines. Figs. 1.2a and b were generated using PDB files 
3PC2 and 1M54, respectively. (c) Proposed catalytic mechanism for H2S generation from 
cysteine by CBS. The resting enzyme exists as an internal aldimine, which reacts with cysteine 
to form the external aldimine of cysteine. Elimination of H2S leads to formation of an 
aminoacrylate intermediate, which reacts with homocysteine (cysteine or water) to form the 
external aldimine of the product cystathionine (or lanthionine or serine). The catalytic cycle is 
completed upon release of product and reformation of the internal aldimine. 
1.2.1.2 Catalytic Mechanism of CBS  
 The active site of CBS is lined with residues that position the substrates and cofactor for 
catalysis. PLP is covalently linked to an active site lysine (Lys119 in hCBS and Lys88 in dCBS) 
and its phosphate moiety is enveloped by a glycine-rich loop (Thr260- Gly259-Gly258-Thr257-
Gly256, hCBS numbering) (Fig. 1.2B). Asn149 and Ser349 form hydrogen bonds with the 
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exocyclic oxygen and pyridine nitrogen, respectively (19,20). Replacement of the corresponding 
serine in yeast CBS (yCBS) by alanine results in the complete loss of activity, while replacement 
with aspartate results in ~80 fold lower activity despite the mutants having only two-fold lower 
PLP occupancy (22). Fluorescence and resonance Raman studies demonstrate that the PLP exists 
in two tautomeric forms: an active ketoenamine and an inactive enolimine (23-25). Asn149 helps 
stabilize the active ketoenamine tautomer. Perturbations in the active site hydrogen-bonding 
network can influence the tautomeric equilibrium, and, as described below is one mechanism by 
which the heme cofactor exerts its effects on the active site (23,25). The first step in the catalytic 
cycle (Fig. 1.2C) is the binding of serine or cysteine (Fig. 1.2C) to the active site followed by 
displacement of the lysine residue that forms an internal aldimine with PLP (14). Abstraction of 
the α-proton from the resulting external aldimine of serine/cysteine generates a carbanion 
intermediate. In the crystal structure of dCBS obtained at 1.7 Å resolution, the carbanion 
intermediate with serine was captured and revealed how the active site stabilizes this reactive 
species (21). The Cα atom is clearly sp
2
 hybridized in this intermediate and the ε-amino group of 
Lys88 is within 2.1, 2.5 and 3.0 Å of the Cα, imino nitrogen of the Schiff base and C4A of PLP, 
respectively, where the negative charge is predominantly localized. Elimination of H2O or H2S 
from the external aldimine of serine or cysteine, respectively, leads to formation of the 
aminoacrylate intermediate, which was also captured in a crystal structure of dCBS obtained at 
1.55 Å resolution (21). In this structure, the Cα is also clearly sp
2
 hybridized and the ε-amino 
group of Lys88, which is swung away from Cα, is parked near the oxygen atoms of the 
phosphate moiety of PLP. The Cβ of the aminoacrylate intermediate is positioned for 
nucleophilic attack by the thiolate of homocysteine (to generate cystathionine), or cysteine (to 
generate lanthionine) or by water (to generate serine). The final step preceding product release 
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involves a second transchiffization reaction in which the active site lysine displaces the product 
and the enzyme returns to its resting internal aldimine state. 
1.2.1.3 Kinetics of H2S Generation by CBS  
 Detailed steady-state kinetic analyses of H2S generation by human and yeast CBS have 
been reported (9). In addition to the canonical β-replacement reaction in the transsulfuration 
pathway (Eq. 1.1), CBS catalyzes at least three other reactions with a combination of cysteine 
and homocysteine as substrates, leading to H2S production (Eqs. 1.2, 1.3, and 1.4). The CBS 
active site has two pockets for binding amino acids that are designated as sites 1 and 2. 
 Serine + Homocysteine → Cystathionine + H2O  [1.1]  
 Cysteine + Homocysteine → Cystathionine + H2S  [1.2]  
 Cysteine → Serine + H2S     [1.3]  
 Cysteine + Cysteine →Lanthionine + H2S   [1.4] 
Site 1 binds the amino acid that forms the external aldimine with PLP while site 2, binds the 
nucleophilic amino acid (9). At saturating substrate concentrations, the specific activity for the β-
replacement of cysteine by homocysteine (reaction 2) is ~4-fold higher than for the canonical β-
replacement of serine by homocysteine (reaction 1). H2S generation from one (reaction 3) or two 
(reaction 4) moles of cysteine results in serine or lanthionine and  is ~40-fold and ~20 fold lower, 
respectively than the rate of H2S generation from cysteine and homocysteine (9).   
 Within the cell, the efficiency of each CBS-catalyzed reaction is dictated in part by the 
relative concentrations of the individual substrates and the Km values are high for both yeast and 
human CBS relative to the intracellular concentrations of their amino acid substrates. The Km for 
cysteine for hCBS at site 1 is 6.8 ± 1.7 mM and higher still for site 2 (27.3 ± 3.7 mM). For 
yCBS, the Km values for cysteine at sites 1 and 2 are 3.6 ± 1.7 mM and 33 ± 3.7 mM, 
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respectively. Homocysteine only binds to site 2 and the Km s for yeast and human CBS are 0.13 
± 0.02 mM and 3.2 ± 1.3 mM, respectively (9). Simulations were performed using the steady-
state kinetic data for hCBS at physiological concentrations of substrate (560 µM serine, 100 µM 
cysteine and 10 µM homocysteine). The simulations predicted that ~96% of H2S derived from 
hCBS is via β-replacement of cysteine by homocysteine with the remainder being contributed by 
the other two reactions (9,23).   
 Pre-steady state kinetic analysis and characterization of reaction intermediates was first 
reported for yCBS using stopped flow spectroscopy (26-28). The heme in hCBS interferes with 
enzyme-monitored pre-steady state kinetic analysis by masking the PLP absorbance. Kinetic 
analysis of a heme-less hCBS variant lacking the N-terminal heme domain was limited by its 
poor stability (29). To circumvent these limitations, we have employed difference UV-visible 
stopped-flow spectroscopy to characterize intermediates in the hCBS-catalyzed reaction (25), an 
approach, that we used previously to demonstrate the intermediacy of an aminoacrylate 
intermediate in dCBS (21). The rate of aminoacrylate formation is ~2.5-fold faster with serine 
than with cysteine in the reaction catalyzed by hCBS and product release appears to limit the 
overall reaction rate (25).  
1.2.1.4 Allosteric Regulation of CBS by Heme 
 The N-terminal heme domain in CBS is devoid of any secondary structure. The heme is 
hexa-coordinate and its histidine and cysteine axial ligands were predicted by EPR, extended X-
ray absorption fine structure (30)(32) and resonance Raman spectroscopy (31). The UV-visible 
spectrum of ferric CBS exhibits a Soret peak at 428 nm and a broad α/βabsorption band centered 
at 550 nm. In the ferrous state, the Soret peak shifts to 449 nm with concomitant sharpening of 
the αand βabsorption bands at 571 nm and 540 nm (32). Mutation of either heme ligand 
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diminishes hCBS activity (by ~9-fold) despite full PLP saturation in the C52A and C52S mutants 
and 75% saturation in the H65R mutant (33). On the other hand, heme saturation is greatly 
reduced in the heme ligand mutants (19% and 40% in the cysteine and histidine ligand mutants, 
respectively) compared to wild-type CBS. The C52S or C52A mutants have five-coordinate 
high-spin heme with a Soret peak blue-shifted from 428 to 415-417 nm in the ferric form and 
from 449 nm to 423 nm in the ferrous form (33). In the ferrous-CO state, the Soret peaks of the 
mutants (at ~422 nm) are virtually identical to that of wild-type enzyme, consistent with the 
substitution of the cysteine ligand by CO. The Soret peaks in the ferric, ferrous and ferrous-CO 
states in the H65R mutant are at 424, 421 and 420 nm, respectively, consistent with the presence 
of a low-spin heme (33).  
 While the role of the heme domain in CBS has been debated, there is growing evidence 
that it regulates CBS activity in response to changes in the heme spin-or ligation-state (34-36). 
The ferrous heme ligands CO and NO, inhibit CBS activity (34,37). Ferrous-NO CBS is five-
coordinate with a broad Soret peak at ~390 nm (34). CBS exhibits nonequivalent binding sites 
for CO with KD values of 1.5 ± 0.1 µM and 68 ±14 µM for full-length hCBS and 3.9 ± 2 µM and 
50 ± 8 µM for the C-terminal truncated form (39,40). Binding of NO to full-length CBS exhibits 
a KD of 30 ± 5 µM for NO (38). Binding of CO to full-length CBS inhibits enzyme activity with 
Ki value of 5.6 ± 1.9 µM (37). The redox potential of the heme is −350 ± 4 mV (9) and -287 ± 2 
mV (39) in full-length and truncated hCBS, respectively. This difference between the full-length 
and truncated forms suggests that the regulatory C-terminal domain modulates the heme redox 
potential. Despite the low reduction potential of the CBS heme, reversible regulation by CO can 
be achieved with physiologically relevant reductants (40). The diflavin oxidoreductases, human 
methionine synthase reductase and novel reductase 1, reduce ferric CBS and the ferrous-CO 
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species is formed in the presence of NADPH and CO.  
 Communication between the heme and PLP domains occurs via an α-helix whose N-
terminal end leads in from the glycine rich loop harboring the conserved T257 and T260 residues 
that make contact with the phosphate moiety of PLP. At the C-terminal end of the helix, Arg266 
is involved in a salt-bridge interaction with the heme ligand, Cys52. Changes in the heme 
coordination state e.g. by formation of the ferrous-CO species, is predicted to disrupt the salt 
bridge between Cys52 and Arg266, displacing the α-helix, which in turn is propagated to the 
PLP site shifting the tautomeric equilibrium towards the enolimine (24). Interestingly, 
replacement of Arg266 by methionine, a mutation described in homocystinuric patients, also 
results in the predominance of the inactive enolimine. Similarly, substitutions at Thr257 and 
Thr260 in the PLP domain stabilize the inactive enolimine tautomer leading to significant loss of 
CBS activity (41). Interestingly, these CBS mutations impact the H2S and cystathionine-
producing versus H2O and cystathionine-producing reactions unequally, suggesting that that 
these two activities can be differentially regulated (41).  
1.2.1.5 Allosteric Regulation of CBS by AdoMet 
 AdoMet binds to the C-terminal regulatory domain (42) and enhances CBS activity ~2-3 
fold (43). Truncation of the C-terminal domain in hCBS leads to loss of AdoMet-dependent 
regulation, increases CBS activity and also decreases its propensity for aggregation (44). Hence, 
the regulatory domain exerts an autoinhibitory effect that is alleviated either upon AdoMet 
binding, by activating mutations or by deletion of the entire domain (45-47). The architecture of 
the regulatory domain and its juxtaposition relative to the catalytic domain was first visualized in 
the structure of full-length dCBS (Fig. 1.2A). The secondary structures the two CBS domains are 
slightly different: β-α-β-β-α-α-βfold in one (spanning residues 416-468 in hCBS) and α-β-α-β-β-
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αin the second (residues 486-543). The AdoMet binding sites in CBS is predicted to reside in the 
β-sheet-lined cleft between the two CBS domains.  
1.2.1.6 Other Mechanisms for Regulation of CBS Activity  
 As a junction enzyme in sulfur metabolism, CBS is the locus of complex regulation. 
AdoMet is an allosteric regulator, which activates CBS under conditions of methyl group 
sufficiency (48,49). As noted above, gaseous signaling molecules like NO and CO bind to the 
heme in CBS and inhibits its activity (34,37,41,50,51), which is reversed upon air oxidation (40). 
Sumoylation of CBS decreases its activity (50). Lys211 in the catalytic core of human CBS 
appears to be the site of sumoylation. In addition, the C-terminal regulatory domain of CBS is 
needed for sumoylation. CBS is reportedly inhibited by lanthionine synthase C-like protein 1 
(LanCL1) in the presence of glutathione (52). Under oxidative stress conditions, when oxidized 
glutathione levels rise, inhibition by LanCL1 is alleviated providing a mechanism for increasing 
transsulfuration flux and consequently, glutathione synthesis. 
1.2.2 -Lyase Cystathionine (CSE) 
1.2.2.1 Structural Organization of CSE 
 Human CSE (hCSE) is a homotetrameric enzyme that catalyzes the second step in the 
transulfuration pathway cleaving cystathionine to cysteine, α-ketobutyrate, and ammonia (Fig. 
1.3A). The crystal structures of yeast (yCSE) and hCSE are available at 2.6 Å resolution each 
(53,54). Each hCSE monomer comprises a large N-terminal PLP-binding domain (residues 1-
263) and a smaller C-terminal domain (residues 264-401) (Fig. 1.3A). The yCSE monomer 
comprises three domains: an N-terminal domain, which interacts with the active site of a 
neighboring monomer, a middle catalytic domain and a small C-terminal domain. The yCSE 
catalytic and C-terminal domains are organized as in hCSE while the N-terminal extension 
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interacts with the active site of the neighboring subunit, is not present in hCSE and comprises an 
extended loop, an α-helix and a β-strand (53).  
 Mutations in CSE, inherited as an autosomal recessive disorder, results in 
cystathioninuria, which is often benign (55). Cystathioninuria can be secondarily associated with 
hepatoblastoma, neuroblastoma, poor development, cystic fibrosis and Down’s syndrome.  
1.2.2.2 Catalytic Mechanism of CSE 
 Like CBS, CSE also catalyze various reactions leading to H2S biogenesis in addition to 
catalyzing the canonical reaction in the transsulfuration pathway (8,23). TPLP is covalently 
linked to Lys212 in hCSE via a Schiff base and its mutation to alanine reduces H2S production 
~80-fold compared to wild-type enzyme. Several active site residues are engaged in hydrogen 
bonding interactions with PLP (53,54); Asn187 with the pyridine nitrogen and Gly90, Leu91, 
Ser209 and Thr211 from one subunit and Tyr60 and Arg62 from an adjacent subunit with the 
phosphate moiety (Fig. 1.3B). Replacement of Asn187 with alanine or glutamic acid results in 
complete loss of H2S production while substitutions of Ser209 and Thr211 by alanine result in a 
modest ~1.5 fold decrease in H2S production (56). Interactions between Tyr60 and Arg62 
contributed by the N-terminal domain of a neighboring monomer and the phosphate group of 
PLP helps to stabilize the active site, which is located at the interface between adjacent subunits. 
Multiple sequence alignment of human, yeast, mouse, rat and slime mold CSEs reveals that 
Tyr60 and Arg62 are conserved in all five sequences (56). Substitution of Tyr60 with threonine 
or alanine results in an ~5-8 fold decrease in hCSE activity, while replacement of Arg62 with 
alanine or lysine results in an ~10-36 fold decrease in activity (56).  
 CSE belongs to the γ-family of PLP-dependent enzymes, which catalyze elimination 
reactions at the γ-carbon. However, in the case of CSE, the specificity is not high and the enzyme 
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catalyzes reactions at both the β-and γ-carbons of the substrate. In the first step, the substrate (i.e. 
cystathionine or cysteine) forms a Schiffs base with the PLP via a transaldimination reaction, 
freeing the active site Lys212 residue. In the next step, Lys212 presumably acts as the general 
base and abstracts the α-proton from bound substrate. When cystathionine is the substrate, 
cleavage of the C-γ-S bond is promoted by a second proton abstraction from Cβ resulting in the 
subsequent elimination of cysteine. Hydrolysis of the resulting imine intermediate yields α-
ketobutyrate and ammonia. Alternatively, when cysteine is the substrate, the C-β-S bond is 
cleaved, releasing H2S (Fig. 1.3C). A second transaldimination reaction regenerates the resting 
internal aldimine. UV-visible spectroscopy based pre-steady state kinetic analysis of the reaction 
catalyzed by yCSE suggests that product release constitutes the rate-limiting step (57).  
 The specificity of the hCSE-catalyzed α,γ-elimination versus α,β-elimination is proposed 
to be governed by the hydrophobicity of the residue at position 339 (53,56). This hypothesis was 
tested by replacing Glu339 with lysine, alanine and tyrosine, which increases hydrophobicity in 
the following order: Y>A>K>E. E339K, E339A and E339Y show approximately 1.8-, 3.2- and 
7.2-fold increase, respectively in the catalytic efficiency of H2S production from cysteine as 
compared to wild-type enzyme (56), consistent with the view that enhancing the hydrophobicity 





Figure 1.3. Structure and catalytic mechanism of CSE. (a) Structures of tetrameric hCSE 
comprising an N-terminal catalytic domain (red) and a C-terminal domain (blue). PLP is shown 
in stick representation (cyan). (b) Close-up of the active site of hCSE. Hydrogen bonds between 
PLP and amino acids lining the active site are shown as dotted lines. The red labels denote 
residues contributed by a neighboring subunit. Figs 1.3a and b were generated using PDB file 
2NMP. (c) Proposed catalytic mechanism of CSE for H2S generation. Cysteine reacts with the 
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resting enzyme and forms the external aldimine of cysteine. Abstraction of the α-proton from 
cysteine leads to formation of cysteine-ketamine intermediate. Cleavage of the C–β–S bond 
eliminates H2S and leads to formation of the aminoacrylate intermediate, which undergoes 
hydrolysis to give pyruvate and ammonia. In the final step, free PLP rebinds with the Lys212 to 
regenerate the resting internal aldimine.  
1.2.2.3 Kinetics of H2S generation by CSE 
 Detailed steady-state kinetic analysis of hCSE revealed that in addition to the canonical 
cystathionine cleavage reaction in the transsulfuration pathway (Eq. 1.5), the enzyme can 
catalyze five distinct H2S-generating reactions in the  presence of cysteine and/or homocysteine 
(Eqs. 1.6-1.10) (8).  
 L-Cystathionine + H2O →L-Cysteine + α-Ketobutyrate + NH3 [1.5] 
 L-Cysteine + H2O → L-Pyruvate + NH3 + H2S    [1.6] 
 L-Cysteine + L-Cysteine →L-Lanthionine + H2S    [1.7] 
 L-Homocysteine + H2O →L-Homoserine + H2S    [1.8] 
 L-Homocysteine + L-Homocysteine → L-Homolanthionine + H2S [1.9] 
 L-Homocysteine + Cysteine → L-cystathionine + H2S   [1.10] 
Unlike hCSE (8), rat CSE reportedly utilizes cystine, the oxidized disulfide form of cysteine, as a 
substrate for H2S production (58). However, the availability of cystine in the reducing cellular 
milieu is questionable and the immediate product of the reaction is cysteine persulfide, which is 
highly unstable. Under maximal velocity conditions, the highest rate of H2S production is 
observed for reaction 9, i.e. γ-replacement of homocysteine by a second mole of homocysteine 
while the lowest rate is observed for reaction 6, i.e. α,β−elimination of cysteine (8). At 
physiological substrate concentrations, the highest rate of H2S production is predicted to occur 
via the α,β−elimination reaction of cysteine and the lowest rate from the β−replacement of 
cysteine by a second mole of cysteine (Eq. 1.7).  
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 CSE exhibits two substrate-binding sites: site 1 at which the Schiff base is formed 
between PLP and an amino acid and site 2 where the nucleophilic second amino acid binds. The 
Km for cysteine at site 1 (1.7 ± 0.7mM) is ~1.6-fold lower than for homocysteine (2.7 ± 0.8 mM) 
while for the Km for homocysteine at site 2 (5.9 ± 1.2 mM) is ~6-fold lower than for cysteine (33 
± 8 mM). The lower Km for cysteine versus homocysteine at site 1 together with the higher 
cellular concentration of cysteine (~100 µM) versus homocysteine (<10 µM), explains the 
predominance of reaction 6 versus 9 at physiologically relevant substrate concentrations (8).  
 The relative contributions of the various CSE-catalyzed H2S producing reactions has 
been estimated at physiologically relevant substrate concentrations (5 µM cystathionine, 100 µM 
cysteine and 10 µM homocysteine) and low (10 µM), moderate (40 µM) and severe (100 µM) 
hyperhomocysteinemia (8). Simulations predict that under normal and hyperhomocysteinemic 
conditions, ~87-99.5% of the total H2S is derived via α,β-elimination of cysteine and α,γ-
elimination of homocysteine, while the remaining three reactions collectively contribute very 
little. Between the two major H2S contributing reactions, the α,β-elimination of cysteine 
predominates (~71%) at normal homocysteine concentrations while the α,γ-elimination of 
homocysteine is the major H2S producer accounting for ~61% and ~78% H2S, respectively under 
moderate and severe hyperhomocysteinemic conditions (8).  
 Preliminary pre-steady state kinetic analyses of the yCSE-catalyzed reaction were 
performed at 5 and 30 °C (59). An aminocrotonate intermediate was detected (λmax = 480 nm) 
upon rapid mixing of yCSE with cystathionine but not with L-cysteine. Conversion of the 
aminocrotonate intermediate to products represents the rate-limiting step in the CSE-catalyzed 
cleavage of cystathionine (57).  
1.2.2.4 Regulation of CSE  
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 Unlike CBS, mechanisms for regulating CSE activity are not well understood. H2S 




/calmodulin-dependent regulation of purified hCSE has not been observed in 
our laboratory (Chiku and Banerjee, unpublished results). A recent study on rat CSE (60), reports 
the rate of H2S production was low in the presence of 2 mM cysteine and 0-100 nM Ca
2+ 
and 
increased 5-fold when 50 µM PLP was added to the reaction mixture. At higher Ca
2+ 
concentrations (0.3 -3.0 µM), the rate of H2S production was ~2.5-fold higher in the presence or 
absence of PLP. Calmodulin (1 µM) had no effect on H2S production by CSE. These findings 
suggest that CSE is not regulated by calmodulin and that low Ca
2+ 
enhances H2S production but 
only in the presence of exogenous PLP while high Ca
2+ 
concentrations (300 nM to 3 µM) inhibit 
CSE (60). While CSE can be sumoylated in vitro (50), the physiological relevance of this 
modification is not known. Mammalian CSE has two conserved CXXC motifs. However, their 
involvement in redox-dependent regulation of CSE activity is not known.  
1.2.3 Mercaptopyruvate Sulfurtransferase  
1.2.3.1 Structural Organization of MST  
 MST functions on a catabolic arm of cysteine metabolism and acts downstream of CAT 
to produce H2S (58,61). CAT or aspartate aminotransferase, can use cysteine as a substrate to 
produce 3-mercaptopyruvate in the presence of alpha-ketoglutarate. 3-Mercaptopyruvate is a 
substrate for MST, which transfers the sulfur group to a catalytic cysteine residue forming an 
enzyme-bound persulfide and releasing pyruvate. In the second half reaction, the sulfane sulfur is 
transferred to a thiol acceptor e.g. cysteine, homocysteine, dihydrolipoic acid, GSH or 
thioredoxin and subsequently released as H2S (62-64). The MST-bound persulfide can also be 
transferred to non-thiol acceptors like KCN to form thiocyanate (65). Recently an alternative to 
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the transamination pathway has been reported for the production of 3-mercaptopyruvate from D-
cysteine in a reaction catalyzed by D-amino acid oxidase (12). The latter, is expressed in 
multiple tissues and is most abundant in the cerebellum and kidney (12). Defects in the MST 
gene are inherited as an autosomal recessive disorder known as mercaptolactate-cysteine 
disulfiduria (66). The condition is characterized by excessive excretion of mercaptolactate-
cysteine disulfide in the urine, with or without mental retardation. Mercaptopyruvate is oxidized 
by lactate dehydrogenase to mercaptolactate and reacts subsequent to export, with extracellular 
cysteine to form the mixed disulfide of mercaptolactate and cysteine (67).  
 The crystal structures of MST from E. coli and Leishmania major have been solved at 2.8 
Å and 2.1 Å resolution, respectively (68,69). Recently, our laboratory has obtained the structure 
of the product complex of hMST at 2.15 Å resolution with pyruvate and persulfide bound at the 
active site (64). Both bacterial and human MST are comprised of two domains connected by a 
linker, which are structurally similar to the rhodanese domain (Fig. 1.4A). The Leishmania MST 
has an extra ~80 amino acids long domain that shares structural homology with the 
immunosuppressant FK506-binding protein and to macrophage infectivity potentiator protein, 
both of which exhibit peptidyl prolyl cis-trans isomerase activity (68). Expression of a C-
terminally truncated Leishmania MST yields a misfolded protein devoid of catalytic activity 
(70). The C-terminal domain in the L. major MST is postulated to be involved in protein folding 






Figure 1.4. Structure and catalytic mechanism of MST. (a) Structure of human MST, which 
comprises an N-terminal domain (yellow) connected to the catalytic domain (blue) by a linker 
(red). (b) Close-up of the active site of hMST showing a persulfide on Cys248 and pyruvate 
(hydrogen bonds are represented by dotted lines). Figs. 1.4a and b were generated using PDB file 
4JGT. (c) Reaction scheme for CAT/MST-dependent H2S generation. (1) CAT catalyzes the 
transamination between cysteine and α-ketoglutarate to generate mercaptopyruvate and 
glutamate. (2) MST catalyzes the sulfur transfer from mercaptopyruvate to an active site 
cysteine, giving pyruvate and MST-bound persulfide. The latter reacts with thiols or thioredoxin 
(in the presence of NADPH and thioredoxin reductase) to generate H2S.  
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1.2.3.2 Catalytic Mechanism of MST 
 A conserved cysteine residue (Cys248 in hMST) plays a key role in the catalytic 
mechanism of this enzyme (Fig. 1.4B). All three available MST structures exhibit persulfides at 
the active site cysteine residue, which represents the product of the MST-catalyzed sulfur 
transfer from 3-mercaptopyruvate. Substitution of the corresponding active site cysteine with 
serine in rat MST (rMST), results in complete loss of activity (71). Two conserved arginine 
residues (Arg188 and Arg197 in hMST) (Fig. 1.4B) are proposed to be important for proper 
positioning of the substrate and their replacement with glycine is deleterious for rMST activity. 
The R187G and R196G mutations increase Km for 3-mercaptopyruvate by 10-and 60-fold, 
respectively and decrease kcat 4-and 870-fold, respectively. Based on the Leshmania MST crystal 
structure, a serine protease-like catalytic triad, comprising Ser255-His75-Asp61 was predicted to 
be a common feature of the MST family. The catalytic triad is proposed to play a role in 
polarizing the carbonyl bond in the substrate to assist in the nucleophilic attack by the active site 
cysteine (68). The crystal structure of hMST confirms the presence of a serine protease-like 
catalytic triad (Ser250-His74-Asp63) in the active site (64).  
 Enzymes belonging to the sulfurtransferase family catalyze the transfer of a sulfur atom 
from a sulfur donor to a nucleophilic acceptor. Based on steady-state kinetic analysis of bovine 
MST, the enzyme was proposed to use a sequential mechanism (72). Based on the structure of 
hMST containing a mixture of the product complex (Cys248-SSH and pyruvate) and an 
unproductive intermediate (3-mercaptopyruvate in a disulfide linkage with Cys248), we have 
proposed a detailed reaction mechanism (Fig. 1.4C) (64). The conserved arginine residues, 
Arg188 and Arg197, interact via hydrogen bonds with the carboxyl group of mercaptopyruvate 
while Arg197 also hydrogen bonds with the carbonyl group of the substrate. His74 in the 
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catalytic triad is proposed to function as a general base, abstracting a proton from Ser250, which 
in turn deprotonates Cys248 for subsequent attack on the sulfur of 3-mercaptopyruvate, leading 
to transfer of the sulfur atom to form Cys248-persulfide and pyruvate. Following release of 
pyruvate, an acceptor molecule (e.g. a dithiol or thioredoxin) attacks the sulfane sulfur of the 
cysteine of the cysteine persulfide regenerating MST and forming a new persulfide on the 
acceptor. Nucleophilic attack by the second (or resolving cysteine) on the acceptor releases H2S 
and results in oxidized disulfide product. Sulfur transfer from mercaptopyruvate to cyanide 
generates thiocyanate and pyruvate (65).  
 Dihydrolipic acid, thioredoxin, cysteine, homocysteine and glutathione function as 
acceptors in the in vitro MST assay and a detailed steady state kinetics analysis of H2S 
production by MST in the presence of these acceptors has been reported (64). At pH 7.4 and 37 
°C kinetic studies revealed that hMST exhibits the highest kcat/Km values are obtained in the 








), while the 




) was obtained with glutathione. Based on kinetic simulation at 
physiologically relevant concentrations of acceptors, thioredoxin is predicted to couple most 
efficiently to the MST reaction (64).  
1.2.3.2 Regulation of MST  
 Regulation of the MST/CAT is poorly understood. Ca
2+
 -dependent regulation of MST 
has been reported based on the effect of varying Ca
2+
 concentrations on MST/CAT-dependent 
H2S production in mouse retinal lysate (73). H2S production decreased as Ca
2+
 concentration 
increased (0-2.9 µM) in the presence of cysteine and α-ketoglutarate (substrates for the 
CAT/MST pathway) but not when 3-mercaptopyruvate was used, suggesting that Ca
2+
 regulates 
CAT (73). Calmodulin is not involved in regulation of MST/CAT-dependent H2S production 
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(73). Rat MST has five cysteines and appears to be redox regulated. Of the five cysteines, three 
(i.e. Cys154, Cys247 & Cys263) are surface exposed (74,75). An intersubunit disulfide bond 
forms between Cys154 and Cys263 under oxidizing conditions and can be reduced by 
thioredoxin. Thioredoxin-reduced MST is ~4.6-fold more active than the oxidized form of MST, 
while pretreatment of MST with DTT results in lower activation (~2.3-fold) (62). Human MST is 
a monomer and the cysteine residues that form the intersubunit disulfide in rMST are not 
conserved in hMST (64). The active site cysteine (i.e. Cys247 in rMST) acts as another redox-
sensitive switch with the potential to regulate MST (74). Treatment of rMST with stoichiometric 
oxidants (H2O2 or tetrathionate) results in inhibition due to formation of cysteine sulfenate at the 
active site, which can be reversed by reductants such as DTT or thioredoxin (74). 
1.2.4. The Relative Contributions of CBS, CSE and MST to H2S Production 
 It is not readily possible from the available kinetic data collected under varied buffer, pH 
and temperature conditions, to assess the relative roles of CBS, CSE and MST to H2S production 
in different tissues. As a first step towards addressing this question, our laboratory has initiated 
kinetic studies in a limited set of tissues (murine liver, kidney and brain) at pH 7.4 and at 37 °C 
(3,76). A second key piece of information that is needed to evaluate the contributions of the 
individual enzymes, is their concentrations in a given tissue, which can be estimated using semi-
quantitative Western blot analysis (76). Finally, it is essential that sensitive and reliable methods 
for H2S detection be used to monitor its formation at physiologically relevant substrate 
concentrations. Initial studies in our laboratory evaluating total H2S production in murine tissues 
indicated that in the presence of 100 µM cysteine, liver exhibits the highest rate of H2S 
production (484 ± 271 µmole h
-1 
kg









-1 tissue) (76). Semi-quantitative 
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Western blot analyses suggest that the expression level of all three H2S-producing enzymes 
decreases in the following order: liver>kidney>brain ((76) and Yadav & Banerjee, unpublished 
results).  
 The relative contributions of CBS and CSE to H2S production at physiologically relevant 
substrates concentrations (560 µM serine, 100 µM cysteine and varying homocysteine ranging 
from its normal concentration (10 µM), to those seen under mild (40 µM) and severe (200 µM) 
hyperhomocysteinemia conditions) have been assessed. The kinetic simulations predict that CSE 
is the major H2S producer and accounts for 97% of the H2S production in liver at 10 µM 
homocysteine, with the proportion only increasing under hyperhomocysteinemic conditions (76). 
A comparable analysis including the contribution of MST is needed to provide a more complete 
picture of the quantitative significance of CBS, CSE and MST to H2S production in different 
tissues. To assess the contribution of the MST/CAT pathway to cysteine-derived H2S production, 
the assays need to be conducted in the presence of physiological concentrations of α-
ketoglutarate needed by CAT to convert cysteine to 3-mercaptopyruvate.  
1.3. Enzymology of H2S Oxidation  
1.3.1. Microbial strategies for sulfide oxidation 
 A major reaction of the global sulfur cycle is the oxidation of H2S to sulfate. It is 
instructive to examine the variations in sulfide oxidation strategies used by microbes where the 
pathways are much better understood than in man. In microbes, inorganic sulfur compounds such 
as sulfide, sulfur globules, sulfite, thiosulfate and polythionates are oxidized to sulfate for 
generation of ATP.  
1.3.1.1 Sulfide and thiosulfate oxidation by phototrophic bacteria 
 Green and purple sulfur bacteria utilize both sulfide and thiosulfate as electron donors for 
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photoautotrophic growth (77,78). Oxidation occurs in a stepwise manner with sulfide being 
converted initially to elemental sulfur, which is stored as sulfur globules either in the periplasm 
or on the surface of the outer membrane and utilized when sulfide is limiting. The two major 
enzymes directly involved in sulfide oxidation are SQR (Eq. 1.11) and flavocytochrome c sulfide 
dehydrogenase (Eq. 1.12), a heterodimeric flavoprotein comprising a glutathione reductase-like 
subunit containing an FAD cofactor and a redox-active disulfide and a diheme cyctochrome c 
subunit (79). Flavocytochrome c sulfide dehydrogenase exists in both soluble and membrane 
bound forms and, like SQR, catalyzes the oxidation of sulfide to polysulfide while reducing the 
diheme cytochrome via FAD (79).   
 S
2-
 + Ubiquinoneox → S
0 
+ Ubiquinonered  [1.11]  
 S
2-
 + cyt cox → S
0
 
+ cyt cred    [1.12]  
 Sulfur globules are converted to sulfite via the cytoplasmic dissimilatory sulfite reductase 
pathway (80). The proteins common to bacteria harboring the dissimilatory sulfite reductase 
pathway include a siroheme or siroamide-containing sulfite reductase, a transmembrane electron 
transporting protein complex, a putative siroheme amidase and the product of the dsrC gene. In 
addition, a sulfurtransferase complex and an iron-sulfur cluster-containing NADH 
oxidoreductase, which is proposed to reduce sulfur polysulfides, are also present in some 
bacteria. The transmembrane complex shuttles electrons released during oxidation of H2S to 
sulfite to quinones (77,80). Sulfite is toxic and is further oxidized to sulfate by one of two 
pathways. The first is direct oxidation catalyzed by sulfite oxidase (Eq. 1.13) and the second 
involves oxidation of sulfite to adenosine-5´-phosphosulfate and its subsequent conversion to 
sulfate liberating either ADP or ATP as the co-product (Eqs. 1.14 and 1.15) (81).  
 SO3
2-











 + AMP → APS + 2e
-
    [1.14] 
 APS + PPi (or Pi) → SO4
2-
 + ATP (or ADP) [1.15] 
 Thiosulfate is oxidized to sulfate by the multi-enzyme sulfur oxidizing (Sox) system (Eq. 











and is also present in some green and purple bacteria (77,78,82). It is localized in the periplasm 
and comprises four proteins: SoxAX, SoxYZ, SoxB and SoxCD. In the first step, thiosulfate is 
oxidized to a cysteinyl S-thiosulfonate intermediate bound to SoxY, which is then hydrolyzed to 
sulfate by a dimanganese thiosulfohydrolase, SoxB. The remaining protein-bound sulfane sulfur 
is oxidized to sulfate by SoxCD, a heterotetramer with a molybdenum cofactor-containing 
subunit and a diheme cytochrome c-containing subunit. Electrons released during thiosulfate 
oxidation are transferred to cytochromes and from there, to the electron transport chain. Green 
and purple sulfur bacteria do not have a SoxCD component in their Sox system, and are unable 
to completely oxidize thiosulfate using the Sox system (77,78,83). In these bacteria, the 
remaining sulfane sulfur in the SoxYZ complex is proposed to either be transferred to the 
bacterial sulfur globule pool or, to be oxidized by the dissimilatory sulfite reductase pathway to 
sulfite.  
1.3.1.2 Sulfur oxidation by acidophilic bacteria 
 Acidophilic bacteria such as Acidithiobacillus ferrooxidans and Acidithiobacillus 
thiooxidans, utilize a sulfur dioxygenase to oxidize elemental sulfur to sulfite (Eq. 1.17) (84). 
Thiol-containing proteins are predicted to be involved in mobilization of extracellular octameric 
elemental sulfur and presentation of sulfane sulfur to the periplasmic sulfur dioxygenase, which 
 1/8S8 + O2 + H2O → SO3
2-
 + 2H




does not accept sulfide or elemental sulfur as substrate (84). The product of this reaction, sulfite 
is oxidized to sulfate by sulfite oxidase. Two other enzymes, SQR and thiosulfate quinone 
oxidoreductase are also active in sulfur oxidation in acidophilic bacteria. SQR oxidizes sulfide to 
elemental sulfur which can react abiotically with sulfite to produce thiosulfate (84). Thiosulfate 
can be oxidized to tetrathionate by thiosulfate quinone oxidoreductase with the electrons being 
transferred to quinone.  
1.3.1.3 Sulfur oxidation by Archaea  
 Sulfur-oxidizing Achaea use a variation of the oxidation schemes discussed above. Thus, 
in Acidianus ambivalens, sulfur oxidation is initiated by sulfur oxygenase reductase, a non-heme 
iron protein that catalyzes the disproportionation of elemental sulfur and/or polysulfide to sulfide 
and sulfite (85-87). H2S is oxidized by SQR to elemental sulfur, which can be utilized by sulfur 
oxygenase reductase setting up an energy-yielding cycle between the two enzymes and allowing 
the organism to maximize the energy gained from sulfur compounds (88). Sulfite can be further 
oxidized to sulfate by sulfite oxidase (86) or it can react with elemental sulfur to form 
thiosulfate, which is oxidized to tetrathionate. Alternatively, sulfite can be oxidized to sulfate via 
the APS pathway (89). 
 In the next section, we review the literature on the mitochondrial sulfide oxidation 
pathway focusing on the enzymes, SQR, the persulfide dioxygenase (PDO) and rhodanese. The 
conversion of sulfide to sulfite and thiosulfate by this trio of enzymes most closely resembles the 
components of the sulfide oxidation pathway in acidophilic bacteria with the exception that 
polysulfide is not generated as an intermediate in the mammalian pathway. Instead, as discussed 
below, the persulfide product of SQR is transferred to an as yet unidentified acceptor. Sulfite is 
ultimately oxidized to sulfate by sulfite oxidase in mammals.  
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1.3.2 Sulfide Quinone Oxidoreductase (SQR) 
1.3.2.1 Structural organization of SQR 
 SQR is found in the inner mitochondrial membrane (90) in eukaryotes, which are 
believed to have acquired the nuclear encoded gene from a mitochondrial endosymbiont (90). 
SQR exists as a dimer or a trimer, with one FAD and one redox active disulfide in each 
monomer (91). SQR oxidizes sulfide to a protein-bound persulfide and transfers electrons from 
H2S to ubiquinone via a bound FAD, coupling sulfide oxidation to the electron transport chain 
(Fig. 1.1). Hence, sulfide functions as an inorganic substrate for the ATP-generating electron 
transfer chain (4).  
 Several crystal structures of SQRs have been reported, notably from Acidianus 
ambivalens (88), Aquifex aeolicus (92), and Acidithiobacillus ferrooxidans (93) SQR belongs to 
the family of flavin disulfide reductases that includes glutathione reductase. SQR contains two 
Rossman fold domains and a C-terminal domain that is important for membrane binding (Fig. 
1.5A). The FAD cofactor is found in the first N-terminal Rossman fold domain and can be non-
covalently or covalently bound. In the latter case, a thioether linkage exists between a cysteine or 
a cysteine persulfide and the 8-methylene group of the isoalloxazine ring of FAD (92). The 
catalytic disulfide is located on the re face of the FAD (Fig. 1.5B). A conserved glutamate 
residue in the active site is proposed to serve as a general base for deprotonating H2S (93). The 
ubiquinone-binding site is located on the si face of the FAD and the majority of residues in 
contact with the quinone are hydrophobic including Phe41, Pro43, Gly322, Tyr323, Gln353, 
Tyr411, Phe394 and Phe357 (A. ferrooxidans numbering) (93). The aromatic ring of the quinone 
is sandwiched between the benzene rings of Phe394 and Phe357. The O2 atom of the flavin 
electron donor, and the O4 atom of the quinone acceptor are <3 Å apart. Residues Tyr411 and 
28 
 
Lys391 have been proposed to transfer protons from water for protonation of the reduced 
quinone (92,93). 
 
Figure 1.5. Structure and reaction mechanism of SQR. (a) Structure of A. ferrooxidans SQR 
monomer displaying the N-terminal Rossman fold domains (blue) and the C-terminal membrane 
binding domain (yellow) and the cofactors (green). (b) Close-up of the A. ferrooxidans SQR 
active site viewing the re face of the FAD isoalloxazine ring and decylubiquinone (DUQ) on the 
si face of FAD. Sulfur atoms between the active site cysteine residues are shown as yellow 
spheres. Figs. 1.5a and b were generated using PDB file 3T31. (c) Proposed mechanism of SQR. 
Reaction of H2S reduces the active site disulfide bond and results in the formation of a persulfide 
on one cysteine and a covalent linkage between the other cysteine and FAD. The cysteine bound 
persulfide is released from the enzyme by an acceptor molecule. Reformation of the active site 
disulfide results in reduction of FAD to FADH2. Electrons are then transferred from FADH2 to 
ubiquinone allowing for regeneration of the oxidized active site.  
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1.3.2.2 Catalytic Mechanism of SQR 
 The catalytic cycle of SQR is initiated by nucleophilic attack of the sulfide on the 
disulfide resulting in the formation of a persulfide and a cysteine thiolate (Fig. 1.5C) (88,92-95). 
The cysteine thiolate attacks the FAD cofactor forming a C4A adduct. Nucleophilic attack of an 
acceptor on the sulfane sulfur results in reformation of the active site disulfide and subsequent 
two-electron transfer to the FAD results in formation of FADH2. Electron transfer from FADH2 
to ubiquinone regenerates FAD.  
 In bacterial SQRs, multiple rounds of electron transfer occur from sulfide to quinone 
without release of the persulfide at the end of each catalytic cycle (88,92-95). Instead, the 
catalytic cycle repeats until the maximum length of the polysulfide product that can be 
accommodated in the active site is obtained, at which point two consecutive nucleophilic attacks 
by the sulfide results in product release and reformation of the active site disulfide. Snapshots of 
these polysulfide species have been observed in structures of prokaryotic SQRs. The structure of 
A. ambivalens SQR revealed a trisulfide bridge between the two active site cysteines (88), while 
the A. ferrooxidans structure revealed a branched intermediate between the two cysteine residues 
consisting of five sulfur atoms (93,94). In the A. aeolicus SQR structures, both linear and cyclic 
polysulfur intermediates were observed (92). The released product can be soluble polysulfide 
containing up to ten sulfur atoms (96) or an octasulfur ring (92).  
 In contrast, in mammalian SQRs, the persulfide product is transferred to an acceptor at 
the end of each catalytic cycle. Although several molecules have been proposed as acceptors of 
the persulfide product including sulfite and glutathione, the identity of the physiological co-
substrate is not known (95). Human SQR utilizes a number of small molecules as acceptors. It 
exhibits a kcat value of 82 ± 6 s
-1
 in the presence of 1 mM cyanide (95). With sulfite as an 
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acceptor SQR displays a Km value of 0.22 0.02 mM with a kcat of 373 ± 13 s
-1
. In contrast, GSH, 
cysteine an homocysteine display nearly identical Km values of 22 ± 3, 23 ± 4 and 22 ± 3.5 mM 
and kcat values of 113 ± 9, 94 ± 4 and 92 ± 5 s
-1
 respectively (97). As intracellular heptatic 
glutathione concentrations relatively high, 7mM, it is expected that GSH is the primary acceptor 
under physiological conditions (97-99). It is not known whether ETHE1 can directly accept the 
persulfide product from SQR.  
1.3.3 Persulfide Dioxygenase (PDO) 
 PDO, also known as ETHE1, is a soluble, mitochondrial matrix enzyme that catalyzes the 
oxidation of glutathione persulfide to sulfite (13,100,101). However, the physiological substrate 
is not known unequivocally. PDO contains a mononuclear non-heme iron in its active site (102) 
(103). Mutations in PDO result in ethylmalonic encephalopathy, an autosomal recessive disorder 
that results in developmental delay hemorrhagic diarrhea, acrocyanosis, petechiae, and 
progressive neurological failure (100,104,105). The clinical profile of ethylmalonic 
encephalopathy includes high levels of lactate, high C5 and C4 acylcarnitine levels in blood, 
increased ethylmalonic acid concentrations in urine and cytochrome c oxidase deficiency in 
muscle and brain (100,106,107). PDO deficiency leads to accumulation of thiosulfate and sulfide 
with the latter inhibiting cytochrome c oxidase and possibly other enzymes and accounting in 
part for the observed pathology (108).  
 Both glutathione persulfide (GSSH) and CoA persulfide (CoA-SSH) serve as substrates 
for human PDO while cysteine persulfide, glutathione and thiosulfate are not substrates (101). 
The specific activity of the enzyme with CoA-SSH is ~50-fold lower than with GSSH. 
Interestingly, 5 mM glutathione, a high but physiological relevant concentration, increases the 
catalytic efficiency of the PDO ~3-fold. Despite the similarity between PDO and glyoxylase II, 
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the former is unable to hydrolyze S-D-lactoylglutathione and other glutathione thioesters like 
glyoxylase II (103). This is most likely due to a C-terminal loop covering much of the active site 
in the dioxygenase making it smaller than the glyoxylase II active site (102,103).  
1.3.3.1 Structural Organization of Persulfide Dioxygenase 
 PDO has a typical metallo-β-lactamase fold containing two central β-sheets enclosed by 
three helices on each side (Fig. 1.6A). The active site iron is ligated via two histidines and one 
aspartate residue, His84, His135 and Asp154 (Fig. 1.6B). The three remaining coordination sites 
are occupied by water resulting in octahedral coordination, typical for ferrous iron (102,103). 
There are conflicting reports of the oligomeric state of the enzyme indicating it exists as either a 
monomer (101) or a dimer (109).  
 The geometry of the iron site in PDO resembles that of the 2-His-1-carboxylate facial 
triad family of oxygenases (110), a common structural motif that binds mononuclear non-heme 
Fe
2+
. The three coordination sites occupied by water are available for binding ligands such as O2, 
substrates and/or cofactors, and allow the enzymes to tune the reactivity of the iron center 
(111,112). With three coordination sites occupied by solvent, the metal center is not reactive 
towards dioxygen. Substrate binding displaces solvent molecules and results in formation of a 
five-coordinate metal center. Replacement of neutral solvent molecules with an anionic ligand 
can decrease the Fe(III)/Fe(II) redox potential rendering the iron center more susceptible to 
oxidation by dioxygen (111). Hence, substrate binding primes the iron center for dioxygen 




Figure 1.6. Structure and catalytic mechanism of PDO. (a) Structure of the human persulfide 
PDO. The mononuclear non-heme iron is shown in orange. (b) Close up of the active site of 
PDO. The mononuclear non-heme iron is coordinated by the 2His-1Asp facial triad residues. 
Figs. 1.6a and b were generated using PDB file 4CHL. (c) Proposed catalytic mechanism of PDO 
for sulfite generation. Binding of the GSSH substrate displaces coordinated water and promotes 
binding of oxygen to the iron center to form the Fe (III) superoxo intermediate. Resonance 
allows for partial radical cation character of the coordinated sulfur leading to recombination and 
formation of a cyclic peroxo-intermediate. Cleavage of the O-O bond results in a sulfoxy-cation 
and an iron-bound activated oxygen atom which is transferred to the sulfur to sulfoxy-cation. 
Subsequent hydrolysis yields sulfite, and GSH is displaced from the active site upon water 
binding to the metal center. R1 and R2 represent residues glutamate and glycine in the GSSH 
substrate.  
 
 The substrate-binding site is predicted to comprise residues Met226, Leu229, Leu231, 
Pro234, Arg163, Tyr197 and Arg214 based on modeling of GSSH in the active site (109). While 
not predicted to directly interact with the substrate, residues Met226, Leu229, Leu231, Pro234 
line one side of the active site pocket and are predicted to aid in positioning the substrate toward 
the iron center. Arg163 is predicted to be hydrogen bonded with the glutamate portion of the 
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GSSH substrate and Arg214 is predicted to be in hydrogen bond distance of the glycine portion 
of GSSH. Similarly, Tyr197 is predicted to be within hydrogen bonding distance of the cysteine 
portion of GSSH, while the sulfane sulfur of GSSH would be coordinated to the iron center 
(109). 
1.3.3.2 Catalytic Mechanism of PDO  
 Kinetic characterization of human PDO and two mutants mimicking missense mutations 
described in ethylmalonic aciduria patients, T151I and D196N, have been described (101). In the 







corresponds to a kcat of 47 s
-1 at 22 ˚C. Glutathione (5 mM) decreases the KM for GSSH ~1.4 fold 
and increases kcat  ~2.2-fold yielding an ~3-fold increase in kcat/Km. The physiological relevance 
of the  modulation of  PDO activity by GSH is not known. The T152I mutant does not affect the 
Km for GSSH while the kcat is diminished ~4 fold and correlates with an ~2.5 fold lower iron 
content compared to wild-type enzyme. Thr152 is located on the same loop as Asp154, an iron 
ligand, and participates in a hydrogen bonding interaction with the backbone of Leu156, which 
may be necessary for correct positioning of Asp154. The Thr152I mutation would result in loss 
of the interaction with Leu156 possibly leading to repositioning of Asp154 (101).  
 The impact of the D196N mutation is to increase the Km for GSSH ~2-fold while leaving 
the kcat unaltered. Asp196 is located on an internal loop distal from the active site and is proposed 
to hydrogen bond with Phe200 and His198 to stabilize the loop. The D196N mutation likely 
destabilizes this loop. Several other pathogenic missense mutations have been described in 
human persulfide dioxygenase and include Y38C, L55P, T136A, R163Q, R163W, C161Y, 
T164K and L185R (104,105,113). Many of these mutations are predicted to be located near the 
active site and may disrupt metal, substrate binding and/or destabilize the enzyme.  
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 The reaction mechanism proposed for PDO is adapted from that described for cysteine 
dioxygenase (102) and is also based on the general reaction mechanism of mononuclear non-
heme iron oxygenases  (111,112). In the proposed mechanism (101), solvent is displaced from 
the iron upon GSSH binding (Fig. 1.6C). The sulfane sulfur and a nitrogen atom from GSSH 
coordinate to the iron center resulting in a five-coordinate iron species, which is primed for O2 
binding. Binding of O2 results in formation of a Fe (III) superoxo intermediate in which the 
coordinated sulfur acquires a partial radical cation character via resonance. Recombination of the 
Fe(III) superoxo species with the coordinated sulfur atom leads to formation of a cyclic peroxo-
intermediate and is followed by homolytic cleavage of the O-O bond resulting in a sulfoxy-
cation species and a metal-bound activated oxygen atom. Transfer of the activated oxygen to the 
sulfur followed by and hydrolysis yields sulfite. Finally, release of GSH followed by rebinding 
of solvent to the iron completes the catalytic cycle (101). 
1.3.4 Rhodanese 
 Rhodanese is a widely distributed protein found in Archaea, bacteria and eukaryotes 
(114). It is a mitochondrial matrix protein that catalyzes the transfer of a sulfur atom from a 
sulfur donor to an acceptor (Eqs. 1.18-1.19).  
 SO3
2-
 + RSSH → S2O3
2-









   [1.19] 
 Despite extensive studies on rhodanese, its precise physiological function is still not 
known. Historically, rhodanese was thought to be involved in cyanide detoxification due to its 
ability to convert cyanide and thiosulfate to thiocyanate (115,116). In fact, thiosulfate along with 
sodium nitrite is administered to treat acute cyanide poisoning. Cells that are routinely exposed 
to gaseous and dietary intake of cyanide, such as the epithelial cells surrounding bronchioles, 
35 
 
hepatocytes that are proximal to the liver’s blood supply and proximal tubule cells in kidney 
have the highest rhodanese levels (117). However, the activity of rhodanese is confined to the 
mitochondrial matrix, where thiosulfate enters with low efficiency suggesting that a different 
sulfur source than thiosulfate might be used for clearing cyanide (118). Alternatively, rhodanese 
might play a role in sulfur metabolism (13,118), particularly for mitochondrial thiosulfate 
production by transfer of the sulfane sulfur from a donor to sulfite (13).  
1.3.4.1 Structural Organization of Rhodanese  
 Bovine liver rhodanese, which shares 89% sequence identity with the human enzyme, has 
been characterized extensively. This protein is folded into two globular domains of equal size, 
with each containing a five stranded parallel β-sheet enclosed by two α-helices on one side and 
three α-helices on the other (Fig. 1.7A) (119). While both domains have a similar fold, the 
sequence homology is low with only 16% sequence identity between them. The N-terminal 
domain is inactive due to replacement of the catalytic cysteine residue with an aspartate and 
plays a role in forming the active site. The catalytic Cys247 residue in bovine liver rhodanese is 
located at the bottom of a pocket formed between the two domains (Fig. 1.7B). The walls of the 
pocket comprise hydrophobic and hydrophilic regions. The hydrophobic regions consist of 
residues Phe212, Phe106, Tyr107, Trp35, and Val251, and the hydrophilic region comprise 
residues Asp180, Ser181, Arg182, Arg186, Glu193, Arg248, Lys249, and Thr252. The 
persulfide intermediate is stabilized by hydrogen bonds from the backbone amides of Arg248, 
Lys249, Val251 and the hydroxyl group of Thr252. Residues Arg186 and Lys249 located at the 
entrance of the active site pocket and their side chains are positioned to participate in binding and 
positioning of thiosulfate through ionic interactions and to polarize the sulfane sulfur for 
nucleophilic attack by the Cys247 thiol. It is possible that the hydrophobic region lining the 
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active site is important for binding other substrates that contain aromatic or hydrophobic residues 
(119).  
 
Figure 1.7. Structure and reaction mechanism of rhodanese. (a) Structure of Bos taurus 
rhodanese. The protein comprises of two equal sized N-terminal (yellow) and C-terminal (blue) 
globular domains. The linker region between the two domains is shown in cyan. (b) Close up of 
the rhodanese active site. The active site is located at the interface of the two domains. N-and C-
terminal domain residues contribute to a hydrophobic patch (yellow), while C-terminal domain 
residues contribute to a hydrophilic region (blue). Figs. 1.7a and b were generated using PDB file 
1RHD. (c) Catalytic mechanism of rhodanese for thiocyanate generation from thiosulfate. 
Rhodanese catalyzes the sulfur transfer from thiosulfate to an active site cysteine, resulting in 
sulfite and a rhodanese-bound persulfide intermediate. The latter reacts with a sulfur acceptor, in 
this example cyanide, to generate thiocyanate.  
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1.3.4.2 Catalytic Mechanism of Rhodanese 
 The sulfurtransferase reaction catalyzed by rhodanese occurs via a double displacement 
mechanism and involves formation of a stable persulfide intermediate (114,119). The reaction is 
initiated by the nucleophilic attack of the Cys247 thiolate on the sulfane sulfur of thiosulfate 
resulting in formation of an enzyme-bound persulfide intermediate (Fig. 1.7C). Next, sulfite is 
released and followed by binding of a sulfur acceptor, which attacks the sulfane sulfur of the 
persulfide intermediate. In the case of cyanide, the product of this sulfur transfer reaction is 
thiocyanate (119). Release of thiocyanate completes the catalytic cycle.  
 Rhodanese also displays sulfurtransferase activity between a persulfide donor and sulfite 
acceptor (equation 18). The Km values for cyanide and thiosulfate for bovine rhodanese are 0.087 
± 0.009 mM and 16.2 ± 1.6 mM, respectively (13). Similar values have also been reported for rat 
and lugworm rhodanese (13). The human rhodanese displays Km values of 39.5 ± 2.5 mM and 29 
± 4 mM for thiosulfate and cyanide respectively (120). In contrast, the Kms for GSSH and sulfite 
are considerably lower (450 ± 4 µM and 60 ± 10 µM respectively), suggesting that the 
sulfurtransferase activity of rhodanese from GSSH to sulfite might be more physiologically 
relevant than its cyanide detoxification activity (120).  
1.3.5 Mitochondrial Sulfide Oxidation: Unanswered Questions 
 Endogenously produced H2S must be regulated to maintain low intracellular 
concentrations. In mammals, steady-state levels of H2S are governed by flux through the 
synthetic pathways (transsulfuration and CAT/MST) and the sulfide oxidation pathway (3). In 
some prokaryotes, sulfide oxidation is essential for ATP generation. Similarly, low 
concentrations of H2S (0.1-1 µM), can stimulate mammalian mitochondrial ATP production and 
serve as an inorganic source of ATP (4,121,122). An important unanswered question regarding 
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the sulfide oxidation pathway is its organization. Since SQR oxidizes sulfide, it is reasonable to 
propose that it catalyzes the first step in the pathway. The ambiguity arises thereafter since the 
persulfide acceptor of SQR is not known. Both PDO and rhodanese can oxidize persulfide 
forming either sulfite or thiosulfate, respectively. However, the co-substrate for rhodanese is 
sulfite, which is derived from the PDO-catalyzed reaction. This dependence of rhodanese on the 
product of PDO suggests that oxidation of H2S proceeds through SQR, the dioxygenase and then 
rhodanese. The products of this pathway thus configured are thiosulfate and sulfate, which is 
derived by oxidation of sulfite catalyzed by sulfite oxidase. The presence of two routes for sulfite 
removal in the mitochondria is paralleled in microbes where multiple sulfite oxidation routes co-
exist in the same organism, e.g. the oxidation of sulfite by sulfite oxidase or via the adenosine-
5´-phosphosulfate reductase pathway (81).  
 Variants of PDO fused to rhodanese are found in certain bacteria (100). The occurrence 
of fused PDO/rhodanese variants suggests that their proximity enhances utilization of sulfite 
produced by one active site and consumed by the other. However, this order of the pathway is 
brought into question by clinical data on PDO deficient patients and PDO knockout mice in 
which sulfite levels are greatly diminished, as expected, but thiosulfate and H2S levels are 
elevated (100). Elevated thiosulfate in the absence of  PDO activity suggests that an alternative 
route for sulfite exists, which supports production of thiosulfate by rhodanese (101). One branch 
of the cysteine catabolic pathway is initiated by cysteine dioxygenase that oxidizes cysteine to 
cysteinesulfinate, which is further metabolized to 3-sulfinylpyruvate by CAT. 3-sulfinylpyruvate 
is unstable and decomposes to form pyruvate and sulfite. We have posited that the persulfide 
product of SQR is preferentially utilized by rhodanese under conditions of PDO deficiency, 
explaining the observed accumulation of thiosulfate under these conditions (101). However, 
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while cysteine catabolism is up regulated under conditions of cysteine excess (123), it is unclear 
how this pathway responds to PDO deficiency and its role in sulfite production under these 
conditions warrants investigation.  
 In this context, understanding the fate of the persulfide product of SQR is pertinent. 
Bacterial polysulfide products of SQR are stored in sulfur globules until further oxidation to 
sulfate. However, sulfur globules have not been reported in higher organisms and in fact, 
eukaryotic lugworm, rat, and human SQRs require a persulfide acceptor for catalytic turnover 
under in vitro conditions (13,95). The persulfide product bound to the SQR active site might be 
either oxidized directly by PDO or rhodanese or transferred to a small molecule carrier such as 
GSH with the resulting GSSH serving as substrate for the PDO and rhodanese. Sulfane sulfur 
acceptors that support the activity of SQR include sulfite, cyanide, sulfide and glutathione. 
Human SQR has been proposed to utilize sulfite as the physiological acceptor since it displays a 
4-or 13-fold higher catalytic efficiency in the presence of either cyanide or sulfite versus 
glutathione (95). The product of persulfide transfer to sulfite is thiosulfate, which is however not 
a substrate for PDO (101). Of the persulfide donors that have been tested as substrates for PDO 
only CoA-SSH exhibits activity in addition to GSSH (101). Hence, the mechanism by which the 
persulfide product of SQR is transferred to the PDO and rhodanese is an important unanswered 
question in the field.  
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 Hydrogen sulfide (H2S), a gas with toxicity comparable to cyanide is a signaling 
molecule that is capable of inducing a wide range of physiological effects, including acting as a 
vasorelaxant and a cardioprotectant during myocardial ischemia reperfusion. Although H2S has 
several beneficial effects, its concentrations must be strictly regulated to avoid toxicity.  H2S is 
clearance occurs primarily via the mitochondrial sulfide oxidation pathway resulting in 
formation of thiosulfate and sulfate. Several enzymes are involved in this pathway: 
sulfide:quinone oxidoreductase (SQR), persulfide dioxygenase (PDO), rhodanese and sulfite 
oxidase.  Mutation of PDO results in the autosomal recessive disorder ethylmalonic 
encephalopathy (EE). Over 20 PDO mutations have been described in EE patients. Kinetic 
characterization of several EE patient mutations (L55P, T136A, C161Y and R163W), was 
performed to determine the biochemical penalties incurred by these mutations. The mutants 
displayed varying degrees of decreased activity. R163W was the least impacted displaying 18-
fold lower kcat/Km compared to wild-type. L55P, C161Y and T136A displayed decreasing 
activity with 42-, 65- and 200-fold lower kcat/Km values. Similarly, all mutants displayed 
decreased iron content. T136A, R163W, C161Y and L55P displayed 1.4-, 3-, 11- and 10.5-fold 
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lower iron content, respectively, compared to wild-type PDO. The thermal denaturation profiles 
of the PDO mutants revealed altered thermal stabilities with R16W, L55P, T136A and C161Y 
displaying 1.2-, 1.4-, 1.4- and 1.7-fold lower Tm values compared to wild-type PDO. 
2.2 Introduction 
 EE is an autosomal recessive disorder that is associated with pathological effects in the 
brain, gastrointestinal tract and peripheral vessels (1-3). It results in acrocyanosis, petechiae, 
hemorrhagic diarrhea, developmental delay and progressive neurological failure leading to 
necrotic lesions in the deep gray matter of the brain. Patients with EE usually succumb to the 
disease within the first decade of life (4-6).  
 The clinical profile of EE includes increased concentrations of ethylmalonic acid in urine, 
C4 and C5 acrylcarnitines in blood and a deficiency of cytochrome c oxidase in brain and muscle 
tissue (1,2,6). EE is caused by mutations in the ethe1 gene that encodes a PDO, also known as 
ETHE1. Over 20 mutations have been described in the ethe1 gene (3,5,7). PDO is a 
mitochondrial matrix protein that participates in the mitochondrial sulfide oxidation pathway 
where H2S is oxidized to end the products, sulfate and thiosulfate (8-10). In addition to PDO, the 
other enzymes involved in the mitochondrial sulfur oxidation pathway are SQR, rhodanese, and 
sulfite oxidase. PDO catalyzes the second step in the pathway, i.e. the oxidation of glutathione 
persulfide (GSSH) to sulfite (Eq. 2.1) (11,12).  




 [2.1]   
Sulfite can undergo further oxidation by sulfite oxidase to produce sulfate, or sulfur transfer via 
rhodanese and the sulfur donor GSSH, to produce thiosulfate.  
 PDO is a member of the metallo- -lactamase family, and contains a mononuclear 
nonheme iron (10,13). PDO exists as a monomer or a dimer in solution (10,12,14). The structure 
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of human PDO displays a typical  metallo- -lactamase-type fold consisting of two 
central -sheet clusters enclosed by three helices on each side (12,15,16). The mononuclear iron 
is coordinated by a 2-His-1-Asp facial triad consisting of residues His79, His135, and Asp154. 
Three water molecules occupy the remaining coordination sites. The active site iron is located 
inside a large groove that is framed with positively charged residues on one side and a polar 
tyrosine on the other (12). 
 Mutations in PDO lead to an increase in levels of thiosulfate and sulfide in EE patients 
and in ethe1
-/- 
mice (5,8). The majority of patient mutations are clustered near the iron 
coordination residues and the active site pocket suggesting that they may disrupt metal and 
substrate binding and destabilize the enzyme.  To date, only four PDO mutations described in EE 
patients have been characterized. The D196N mutation, located on an internal loop away from 
the active site, has modest effects on enzymatic function, primarily affecting the Km for GSSH, 
which increases 2-fold compared to wild-type PDO. In contrast, the T1521 mutation, located 
upstream the iron ligand Asp154, displayed a 2.5-fold lower iron content and an ~4-fold lower 
kcat. (10). Both mutants showed significantly lower thermal stability (Tm 10-15 ˚C lower) than 
wild-type PDO.  In a separate study, the R163W and R163Q mutations, located near the active 
site and proposed to bind GSSH, were also shown to decrease the Tm (~7-9 ˚C lower). These 
mutants also exhibited significantly lower iron reduction potentials (-310 mV for R163Q and -
370 mV for R163W versus -272 mV for wild-type PDO) (14). While it was shown that the 
mutations resulted in an ~10-fold lower specific activity, kinetic characterization of the Arg163 
mutations was not reported (14).   
 Herein, we report the kinetic characterization of four PDO patient mutations, L55P, 
T136A, C161Y, and R163W. These mutations impact to varying degrees, the kinetics, stability 
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and iron content of PDO compared to the wild-type protein and provide insights into the 
biochemical penalties associated with mutations distal from the active site.  
2.3 Experimental Procedures 
2.3.1 Materials 
 Sodium sulfide, oxidized glutathione, pararosaniline hydrochloride and 2,4,6-tripyridyl-
S-triazine were purchased from Sigma.  
2.3.2 Expression constructs for mutant PDOs  
 The PDO mutations were generated using the QuickChange kit (Stratagene) and the wild-
type PDO expression construct  as a template (10). Primers used in this study are listed in Table 
2.1. The resulting plasmids were transformed into BL21 E. coli cells.  
 
TABLE 2.1 PDO mutagenesis primer sequences. 















2.3.3 Expression and purification of human PDO mutants 
 The recombinant PDO proteins were expressed in BL21 E.coli cells. A Luria Broth (LB) 
culture (200 mL) grown overnight at 37 
o
C was used to inoculate 3 L of LB media. Cultures 
were grown at 28 °C and expression was induced with 100 µM isopropyl-β-D-
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thiogalactopyranoside when the optical density at 600 nm reached 0.5. At the time of induction, 
cultures were supplemented with ferrous ammonium sulfate to a final concentration of 250 M 
and growth was continued for an additional 14 h at 28 °C.  Cells were harvested by 
centrifugation at 2683 x g for 20 min at 4 °C.  The PDO proteins were purified as follows: The 
cell pellet from a 3 L culture was re-suspended in 500 mL of 50 mM Tris buffer, pH 8, 
containing 0.5 M NaCl (Buffer A), 0.1% Tween 20, 1 tablet of protease inhibitor cocktail 
(Roche) and 100 mg of lysozyme (Sigma). DNase (50 mg) and MgCl2 (10 mM final 
concentration) were added to the cell suspension and stirred at 4 °C for 60 min followed by 
sonication on ice with the following pulse sequence: 30 sec burst, 1 min rest for a total burst time 
of 5 min at a power output setting of 6. The resulting sonicate was centrifuged at 8217 x g for 15 
min at 4 °C.  The resulting supernatant was diluted to a final volume of 1 L with Buffer A and 
loaded onto a 20 mL Ni-NTA column equilibrated with the same buffer. The column was 
washed with Buffer A, 20 mM imidazole (500 mL). PDO was eluted from the column with a 
linear gradient ranging from 20-500 mM imidazole.  Protein containing fractions were pooled, 
concentrated, and dialyzed overnight against 50 mM Tris, pH 8.0, 0.25 M NaCl (4 L) and stored 
at -80 °C. Protein concentration was determined using the Bradford reagent with BSA standards.  
2.3.4 Metal analysis 
 Iron content was measured using a colorimetric assay described by Fischer and Price 
(17). Briefly, the protein (10-50 µM) was denatured with 0.5 N HCl and 5% (w/v) trichloroacetic 
acid, mixed for 30 s and subsequently centrifuged for 10 min at 16,000 x g in a microcentrifuge. 
To determine the total iron content, the supernatant (700 µL) was mixed with 300 L of a 1:2:1 
mixture of 4 mM 2,4,6-tripyridyl-S-triazine (TPTZ), 50 % ammonium acetate, and 10 % 
hydroxylamine chloride, and incubated at room temperature for 5 min. Absorbance of the 
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resulting Fe(II)-TPTZ complex as measured at 596 nm. The concentration of Fe was calculated 




 for the Fe(II)-TPTZ complex (17).  
2.3.5 Thermal stability assay 
 Wild-type and mutant PDO thermal stabilities were evaluated as described previously 
(10) by monitoring the increase in absorbance at 600 nm with increasing temperature. For this, 
enzyme (100 g) in Buffer A (final volume 200 l) was placed in a cuvette housed in a Cary 100 
Bio UV/visible spectrophotometer equipped with a heating block connected to a water bath. The 
temperature was increased from 25-70 °C in 5 °C increments.  
2.3.6 Preparation of glutathione persulfide 
 GSSH was prepared anaerobically as described previously (10) by the reaction of 
oxidized glutathione (GSSG) with sodium sulfide (Na2S) in a Coy anaerobic chamber  
(atmosphere of 95:5 N2:H2) (Eq. 2.2).  
 
 GSSG + Na2S  GSSH + GSH    [2.2] 
 
Briefly, solid Na2S was added in 4-fold excess, to an anaerobic solution of 50 mM GSSG in 350 
mM sodium phosphate, pH 7.4 (final volume 5 mL). The reaction vial was immediately sealed to 
prevent loss of Na2S and incubated at 37 °C for 25-30 min. The concentration of GSSH was 
measured using the cold cyanolysis method as described previously (18).  
2.3.7 Oxygen consumption assay 
 The PDO activity of the mutants was measured as described previously (10). The reaction 
mixture consisted of 100 mM sodium phosphate, pH 7.4, and 0.5-170 g of enzyme (final 
volume 1.6 mL) mixed in a Gilson-type chamber containing a Clark oxygen electrode and a 
magnetic stir bar. The reaction was initiated by addition of GSSH. The GSSH concentration was 
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varied from 0.02-4.0 mM to determine the dependence of enzyme activity on substrate 
concentration. All reactions were performed at room temperature (22 °C).  
2.4 Results 
2.4.1 Purification of wild-type and mutant PDOs 
 The recombinant proteins were purified using a one-step protocol and obtained with a 
purity of >95% (Fig. 2.1A). The protein migrates on SDS-PAGE with a molecular mass of ~25 
kDa band, which is consistent with its predicted molecular weight size of 27 kDa. Protein 
preparations of L55P, T136A, C161Y and R163W yielded 65, 21, 40 and 53 mg, respectively 
from 3 L cultures.  
2.4.2 Stability of wild-type and mutant PDOs 
 The thermal denaturation profiles for the mutant PDOs revealed altered stability 
compared to wild-type enzyme (Fig. 2.1B) with R163W being least impacted with a Tm of 53 ± 2 
°C compared to 64 ± 5 °C for wild type enzyme. The L55P and T136A mutants displayed similar 
thermal stabilities, with Tms of 47 ± 6 °C and 44 ± 2 °C, respectively. The C161Y mutation was 






Figure 2.1 Properties of PDO mutants.  A, The purity of wild-type and mutant PDOs (5 g 
each) was evaluated by SDS-PAGE analysis and estimated to be >90%. B, Thermal denaturation 
curves for C161Y (solid circles), L55P (open circles), T136A (solid triangles), R163W (open 
triangles) and wild-type PDO (solid squares). Protein denaturation was monitored by the increase 
in absorbance at 600 nm as described under Experimental Procedures. The data are 
representative of three independent experiments.   
 
2.4.3 Metal Analysis 
 The iron content of wild-type and mutant PDOs was determined using the 2,4,6-TPTZ 
based colorimetric method (17). Of the mutants, T136A displayed the highest iron content (0.58 
mol Fe/mol enzyme) compared to wild-type PDO (0.82 mol Fe/mol enzyme) (Table 2.2). The 
R163W mutant displayed 3-fold lower iron while the C161Y and L55P displayed ~11-fold lower 
iron content than wild-type PDO. Attempts at reconstituting the PDO iron sites with FeCl2 to 















Enzyme Iron Content Vmax Km (GSSH) kcat kcat/Km  











Wild type* 0.82 ± 0.05 113 ± 4 0.34 ± 0.03 47 140 
L55P 0.078 ± 0.005 6.3 ± 0.8 0.86 ± 0.07 2.8 3.3 
T136A 0.58 ± 0.02 1.7 ± 0.2 1.1 ± 0.3 0.8 0.7 
C161Y 0.073 ± 0.001 5.8 ± 0.5 1.2 ± 0.2 2.6 2.2 
R163W 0.27 ± 0.04 12.9 ± 0.8 0.73 ± 0.09 5.6 7.6 
 
a
The kinetic parameters were determined by monitoring O2 consumption in the presence of 
GSSH at 22 ˚C in 100 mM sodium phosphate at pH 7.4, as described under Experimental 
Procedures. *The values for wild-type PDO have been reported previously (10). 
 
2.4.4 Kinetic characterization of PDO mutants 
 The rate of oxygen consumption during enzyme-catalyzed oxygenation of GSSH to 
sulfite (Eq. 1) was monitored using an oxygen electrode (Fig. 2.2). The PDO mutants displayed 
varying effects on specific activity, which was lowered and on Km, which was increased, 
compared to wild-type PDO (Table 2.2). The R163W mutant was the least impacted and 
exhibited an ~9-fold decrease in specific activity and a 2-fold increase in Km. The T136A mutant 
was most impacted displaying a 66-fold decrease in specific activity and a 3.2-fold increase in 






Figure 2.2 Kinetic analysis of PDO activity. The dependence of PDO activity on GSSH 
concentration for A, R163W, B, L55P, C, C161Y and D, T136A PDO. Oxygen consumption by 
PDO in 100 mM sodium phosphate buffer, pH 7.4, was monitored at 22 °C in the presence of 
varying concentrations of GSSH. The data are representative or three independent experiments. 




 Over 20 missense mutations in PDO have been identified in EE patients (3,5,7). The 
majority of these mutations are clustered near the iron binding ligands and the substrate pocket 
(12). In this study, we investigated three mutations (T136A, C161Y and R163W) that are 
proximal and one that is distal from the active site pocket (L55P) (Fig. 2.3A). Overall, these 
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mutations resulted in decreased iron content, thermal stability and altered kinetics. In the human 
PDO structure, Thr136 is located immediately downstream of the iron coordinating ligand, 
His135 (Fig. 2.3B). It participates in hydrogen bonding interactions with the backbone amide 
groups of Gly138 and Cys139, which likely aid in stabilizing the loop and positioning His135 for 
iron coordination. Additionally, Thr136 participates in a hydrogen-bonding network that 
stabilizes an adjacent loop in the -sheet core. The T136A mutation would likely disrupt this 
network and lead to destabilization of the loops causing displacement of H135 and loss of iron. 
Surprisingly, the iron content of the T136A mutant was 70% that of wild-type PDO, but its 
kinetic parameters were severely impacted (Table 2). 
 Leu55 is located on a loop 16.6 Å away from the active site iron (Fig. 2.3C). Both 
upstream and downstream of Leu55, several residues are involved in a hydrogen-bonding 
network that are involved in positioning the iron coordinating residue, His79. Therefore, 
mutation of Leu55 to proline is predicted to cause perturbations originating from the third 
coordination sphere of iron. The mutation leads to 10% iron content compared to wild-type PDO 
and a >40-fold decrease in kcat/Km, with most of the loss in catalytic efficiency expressed on kcat. 
 Cys161 is located on the same loop as the iron coordinating ligand, Asp154, and its 
backbone carbonyl is hydrogen bonded to Arg214 (Fig. 2.3D). Mutation of Cys161 to the larger 
tyrosine residue is expected to lead to loss of the hydrogen bonding interaction with Arg214 and 
to steric clashes with Phe222 and Met226 on the adjacent -helix (Fig. 2.3D).  It likely that the 
mutation would result in repositioning of the loop to accommodate the tyrosine and perturb 
proper positioning of Asp154 needed for iron coordination and Arg163 needed for substrate 
binding. The mutant shows significant loss of iron (10% of wild-type) and a 3.5-fold higher Km 
for the substrate.  
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Arg163 is located near the iron and is downstream of the iron ligand Asp154. Arg163 
participates in hydrogen-bonding interactions with Asp165 and Ser230 and is implicated in 
substrate binding (Fig. 2.3E). Modeling of GSSH in the human PDO structure and the crystal 
structure of Pseudomonas putida PDO in complex with GSH both suggest that Arg163 is within 
hydrogen-bonding distance of the carboxyl group in the glutamate moiety of GSSH (12,16). 
Mutation of Arg163 to tryptophan is predicted to result in a conformational change to 
accommodate the bulkier side chain and reposition the upstream iron binding ligand Asp154. 
The mutation decreases iron content to 33% of wild-type PDO, increases the Km for GSSH ~2-
fold and decreases kcat ~10-fold. A previous study on the R163W mutation reported reduced 
thermal stability and specific activity as found in our study, and also, a significantly lower iron 
reduction potential (14). The sensitivity to iron oxidation would be increased in the R163W 
mutant as a result of its ~100 mV more negative redox potential, further impacting PDO activity. 
Changes in the iron reduction potential might also be true of the other PDO mutations 
characterized in this study explaining the greater magnitude of decrease in their specific 
activities (~9-66-fold) compared to their decrease in iron content (1.4-11-fold) (Table 2.2).  
 The lower catalytic efficiency of the mutants helps explain the metabolic profile observed 
in EE patients and in ethe1
-/- 




Figure 2.3. Structural analysis of PDO mutations. The structure of human PDO (PDB ID: 
4CHL) was use to map the locations of PDO mutations characterized in this study. A, Iron 
(yellow sphere) ligands (His79, His135 and Asp154) that form the 2-His-1-Asp facial triad are 
shown in stick representation. The location of the four residues that are mutated in patients, 
Leu55, Thr136, Cys161 and Arg163, (orange) are shown in stick representation. B, Close-up 
showing the side chain interctions of Thr136, which would be lost in the T136A mutation. The 
hydroxyl group of threonine interacts with the backbone amides of Gly138 and Cys139 
stabilizing the loop and participates in a hydrogen bond network that stabilizes an adjacent loop. 
These interactions are likely important for positioning His135 and stabilizing part of the -sheet 
core of the protein. C, Close-up of Leu55 displays interactions that would potentially be lost due 
to the L55P mutation. Residues upstream (Val54 and Asp52) and downstream (Thr57, Asn77, 
Thr78, H81 and Thr86) of Leu55 participate in a hydrogen-bonding network that interacts with 
the iron ligand His79. This network is likely important for positioning the His79 residue. D, 
Close-up of Cys161 reveals that its backbone carbonyl participates in a hydrogen bond with the 
side chain of Arg214, which likely stabilizes the loop and helps position Asp154. E, Close-up of 
Arg163 reveals that it is engaged in hydrogen bonding interactions with the backbone carbonyl 
of Pro232 and the carboxylate oxygens of Asp165. This network is likely important for 




PDO activity might lead to a redirection of the sulfide oxidation pathway towards thiosulfate 













 for wild type enzyme) would further favor the former. The kcat/Km values for the 






) than wild-type PDO. Under PDO 
deficiency conditions, it is expected that the sulfide oxidation pathway would eventually stall due 
to decreased production of sulfite, which is needed for thiosulfate formation by rhodanese. Under 
these conditions, H2S levels would increase due to the reactivity of GSSH, forming GSSG and 
H2S. The increase in H2S levels would inhibit cytochrome c oxidase and consequently, SQR 
leading to further accumulation of H2S (19,20). The observed increased in thiosulfate in EE 
levels could also result from enhanced H2S oxidation by hemeproteins, which catalyze its 
conversion to thiosulfate (21,22).  
 In summary, we have shown that four of the PDO missense mutations identified in EE 
patients adversely impacted the iron content, thermal stability and kinetic properties of the 
enzyme. Examination of the PDO structure suggests that the functional consequences of these 
mutations are due to perturbations in the positioning and interactions of the iron ligands and in 
the case of R163W, to additionally affecting substrate binding. The observed biochemical profile 
of EE can be explained by a shift in the partitioning of the substrate GSSH produced in the first 
step in the sulfide oxidation pathway, towards rhodanese and thiosulfate production due to 
reduced competition from PDO resulting in increased thiosulfate and eventually, to a buildup of 
H2S levels.  
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Sulfur Transfer and Oxidation Catalyzed by a Persulfide Dioxygenase-Rhodanese Fusion 
Protein 
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 Hydrogen sulfide is a signaling molecule, which is toxic at elevated concentrations. In 
eukaryotes, its clearance occurs via a mitochondrial sulfide oxidation pathway, which comprises 
sulfide quinone oxidoreductase, persulfide dioxygenase (PDO), rhodanese and sulfite oxidase 
and converts H2S to thiosulfate and sulfate. Natural fusions between the non-heme iron 
containing PDO and rhodanese, a thiol sulfurtransferase, exist in some bacteria. Herein, we 
report the kinetic properties and the crystal structure of a PDO-rhodanese fusion protein, (PRF), 
from Burkholderia phytofirmans. The crystal structures of wild-type PRF and of the 
sulfurtransferase-inactivating C314S mutant with and without glutathione bound were 
determined at 1.8, 2.4, and 2.7 Å resolution, respectively. The two active sites are distant and do 
not show evidence of direct communication. The B. phytofirmans PRF exhibited robust PDO 
activity and preferentially catalyzed sulfur transfer in the direction of thiosulfate to sulfite and 
glutathione persulfide; sulfur transfer in the reverse direction, i.e. leading to thiosulfate 
formation, was not detectable. Together with the kinetic data, our bioinformatics analysis reveals 
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that PRF is poised to metabolize thiosulfate to sulfite and is involved in a sulfur assimilation 
pathway rather than in sulfide stress response as seen with the Staphylococcus aureus PRF or in 
sulfide oxidation and disposal as seen with the homologous proteins in mammals. 
3.2 Introduction  
 Hydrogen sulfide (H2S)  is a gas with toxicity comparable to that of cyanide (1). It is also 
a signaling molecule produced by prokaryotes and eukaryotes and elicits a broad range of 
physiological effects (2-4). Notably, it acts as a cardioprotectant during myocardial ischemia 
reperfusion and is implicated in regulation of the cellular stress response, apoptosis, and 
inflammation (5-8). Steady-state H2S levels are governed by the rates of its production and 
clearance (9). In eukaryotes, H2S is produced by the transsulfuration pathway enzymes, 
cystathionine -synthase and cystathionine -lyase, and by the cysteine catabolic pathway 
enzyme, mercaptopyruvate sulfurtransferase (10,11). Sulfide clearance occurs primarily via the 
mitochondrial sulfide oxidation pathway (12,13). Several enzymes are involved in the 
mitochondrial sulfur oxidation pathway: sulfide quinone oxidoreductase, the persulfide 
dioxygenase (PDO, also known as ETHE1), rhodanese, and sulfite oxidase. The main products 
of the sulfide oxidation pathway are thiosulfate and sulfate. PDO is a member of the 2-His-1Asp 
mononuclear iron containing enzyme superfamily and catalyzes the oxidation of glutathione 
persulfide (GSSH) to sulfite (14,15). Mutations in PDO result in ethylmalonic encephalopathy, 
an autosomal recessive disorder (16). Over 20 mutations have been described in the ethe1 gene 
(17). Rhodanese is a thiosulfate sulfurtransferase; in humans, it preferentially catalyzes sulfur 
transfer from GSSH to sulfite producing thiosulfate and GSH (Eq. 3.1) (18).  
 GSSH + SO3
2-





 Rhodanese domains are universal structural modules that occur in one of three variations 
(19). They can be found as tandem repeats as in human rhodanese, which possesses a non-
catalytic N-terminal domain and a catalytically active C-terminal domain (18,20). Alternatively, 
they can be found as a single domain in proteins such as human TSTD1 (21) and E. coli GlpE 
(22), or as natural fusions with other protein domains as in the S. aureus CstB (23). In 
prokaryotes, H2S can be generated via several pathways. It is an end product of the dissimilatory 
sulfate reducing pathway in which sulfate is used as a terminal electron acceptor during 
anaerobic respiration (24). H2S is an intermediate in the assimilatory sulfate-reducing pathway 
where it is produced from sulfite by sulfite reductase and is used as a substrate for cysteine 
synthesis (25). Additionally, H2S can be produced by orthologs of the eukaryotic H2S 
biosynthetic enzymes cystathionine -synthase and cystathionine -lyase and mercaptopyruvate 
sulfurtransferase, which have been identified in several bacterial species and suggested to play a 
role in defense against antibiotic-induced oxidative stress (26). H2S metabolism by prokaryotes 
combined with its toxicity at high concentrations, necessitates mechanisms for regulating its 
levels (27). The sulfide anion efflux transporter described in Clostridium difficile represents one 
mechanism for clearing sulfide via export (28). Additionally, several bacterial species possess 
orthologs of the eukaryotic mitochondrial sulfide oxidation pathway enzymes, and presumably 
dispose of oxidation products of sulfide (23,29,30). 
 Recently, bacterial proteins that are natural fusions between PDO and rhodanese have 
been identified (23). Hereafter, we refer to these fusion proteins as PRF (for PDO rhodanese 
fusion). Bioinformatics analysis reveals that in a subset of these PRFs, e.g. the one from 
Burkolderia phytofirmans PsJN, the PDO domain is fused to a single rhodanese domain, which 
is orthologous to human thiol sulfurtransferase, TSTD1 and distinct from the two-domain human 
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rhodanese (Fig. 3.1A). In another subset, exemplified by CstB (23), the PDO domain is fused to 
two rhodanese domains (Fig. 3.1A). Of these, the first (or middle) rhodanese domain is non 
catalytic while the second (or C-terminal) domain houses the sulfurtransferase activity and, as in 
the case of CstB, oxidizes bacillithiol persulfide and coenzyme A persulfide to thiosulfate 
(23,30). CstB is implicated in protecting against persulfide stress and H2S toxicity (23).  
 The existence of PRFs in nature suggests that their mitochondrial homologs, which exist 
as stand-alone proteins, might interact. Structures of two PRFs are available from structural 
genomic projects. The first is of CstB (PDB ID: 3R2U) in which density for the catalytic 
rhodanese domain is missing. The second structure is of the biochemically uncharacterized 
Alicyclobacillus acidocaldarius PRF (PDB ID: 3TP9), which contains a PDO domain fused to 
two rhodanese domains. Interestingly, these structures reveal the presence of a cysteine-
containing loop in the PDO active site that is absent in the human PDO structure and is not 
predicted in the sequence of BpPRF.  This additional loop is speculated to aid in substrate 
transfer from the PDO domain to the rhodanese domain (23).As CstB is the only PRF that has 
been characterized biochemically to date (23,30), there is a scarcity of information on the roles 
of PRFs in sulfur metabolism in bacteria. 
  In this study, we have characterized the PRF protein from Burkolderia phytofirmans 
(referred hereafter as BpPRF), a gram-negative endophyte originally isolated from onion roots 
(31). In BpPRF, the N-terminal nonheme Fe(II)-containing PDO domain is followed by a 
rhodanese domain containing the signature CRXGX(T/R) active site motif (Fig. 3.1B). 
Interestingly, this motif is more similar to that of sulfurtransferases containing two rather than 
one rhodanese domain. The N-terminal PDO domain of BpPRF displays high sequence identity 
to human PDO (56%) and displays complete conservation of the active site iron binding ligands.  
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 We demonstrate that BpPRF is a bifunctional enzyme that uses the rhodanese domain to 
preferentially catalyze sulfur transfer from thiosulfate to GSH to form sulfite and GSSH and uses 







+ GSSH   [3.2] 
 GSSH + O2  GSH + SO3
2- 
   [3.3] 
The crystal structures of BpPRF provide insights into the architecture and the relative 
juxtaposition of its active sites.  
 
Figure 3.1. Organization of BpPRF and limited sequence comparison. A, Domain 
organization of PRFs. PRFs form S. aureus (SaPRF) and A. acidocaldarius (AaPRF) have an N-
terminal PDO domain, a non-catalytic rhodanese (RHOD) domain and a catalytic rhodanese 
(Rhod) domain. BpPRF displays an N-terminal PDO domain and C-terminal catalytic rhodanese 
domain. B, Sequence alignment of rhodanese active site sequences from human (hTST) and 
bovine (RhoBov) rhodanese, human mercaptopyruvate sulfurtransferase (MST), E. coli single 
domain rhodanese (GlpE), human mitochondrial single-domain sulfurtransferase (TSTD1), S. 
aureus PRF (CstB), B. phytofirmans PRF (BpPRF), A. acidocaldarius PRF (AaPRF). The 
conserved active site cysteine is highlighted in yellow. C, Comparison of the genomic contexts 
of CstB (top) and BpPRF (bottom). The operon encoding CstB (pink) includes a multi-domain 
rhodanese (CstA, red) and an SQR homolog (light green). The adjacent locus includes the 
polysulfide sensing repressor CsTR (yellow) and TauE (purple), a putative sulfite 
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permease/transmembrane sulfur compound exporter. The loci adjacent to BpPRF (pink) include a 
putative peroxidase (cyan) and pyridoxal 4-dehydrogenase (blue), a putative transmembrane 
(TMS)-type transporter (dark green) and a putative LysR-type regulator (orange).  
 
3.3 Experimental Procedures 
3.3.1 Materials  
 The sodium salts of  sulfide, sulfite and thiosulfate, GSH, oxidized glutathione, L-
cysteine, para-rosaniline hydrochloride and 2,4,6- tripyridyl-S-triazine were purchased from 
Sigma. FluoroPure grade monobromobimane was purchased from Life Technologies. 
3.3.2. Expression constructs for BpPRF 
 The cDNA encoding BpPRF was amplified from genomic DNA isolated from 
Burkholderia phytofirmans PsjN (purchased from DSMZ, Braunschweig, Germany), using the 
following primers containing NdeI and HindIII restriction sites (bold font): forward 5′-
TTAATTCATATG TTGATCTTCCG GCAGCTATTC-3′ and reverse 5′-TTAATT 
AAGCTTCTACACGCTGTTTTCAACGACGG-3′. The resulting PCR fragment was cloned 
into a pET28b vector. A C-terminal truncated BpPRF ( C-BpPRF) construct missing the last 4 
residues ( C 354-357), was generated for cryastallography only, using the full-length BpPRF 
expression construct as a template and the following primers containing NdeI and HindIII 
restriction sites (bold font): forward 5′TTAATTCATATGTTGA TCTTCCGGCAGCTATTC-3′ 
and reverse 5′-TTAATTAAGCTTCTATTCAACGA CGCGGCC-3′. The resulting PCR 
fragment was cloned into a pET28b vector. The, C314S mutant, was generated using the 
QuickChange kit (Stratagene) and the wild-type BpPRF expression construct as a template. The 
isolated rhodanese domain was subcloned from the wild-type BpPRF expression construct using 
the following primers containing NdeI and HindIII restriction sites (bold font): forward 5′-
TTAATTCATATGATGACCGAGCC CGATTTGGCG-3′ and reverse 5′-TTAATTA 
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AGCTTCTACTGCGTGGGGACGCTCGC-3′. The resulting PCR fragment was cloned into a 
pET28b vector.  
3.3.3. Expression and purification of BpPRF 
 The recombinant BpPRF protein was expressed in BL21 E.coli. A 200 mL culture in 
Luria Bertani medium was grown overnight at 37 
o
C and used to inoculate a 4  1 L culture in 
the same medium. Cultures were grown at 28 °C and expression was induced with isopropyl-β-
D-thiogalactopyrano-side (100 µM) when the optical density at 600 nm reached 0.5. Cultures 
were supplemented with ferrous ammonium sulfate at the time of induction to a final 
concentration of 250 M and growth was continued for an additional 14 h at 28 °C.  Cells were 
harvested by centrifugation at 2683  g for 20 min at 4 °C.   
 BpPRF was purified as follows. The cell pellet from a 4-liter culture was resuspended in 
500 mL of 50 mM Tris buffer, pH 8, containing 0.5 M NaCl (Buffer A), 1 tablet of protease 
inhibitor cocktail (Roche) and 100 mg of lysozyme (Sigma). DNase (50 mg) and MgCl2 (10 mM 
final concentration) were added to the cell suspension and stirred at 4 °C for 60 min followed by 
sonication on ice with the following pulse sequence: 30 sec burst, 1 min rest for a total burst time 
of 5 min at a power output setting of 6.The sonicate was centrifuged at 8217  g for 15 min at 4 
°C.  The resulting supernatant was diluted 2-fold with Buffer A and loaded onto a 20 mL Ni-
NTA column equilibrated with the same buffer. The column was washed with 500 mL of Buffer 
A containing 30 mM imidazole buffer. PRF was eluted from the column with a linear gradient 
ranging from 30-500 mM imidazole in Buffer A.  Fractions containing the PRF protein were 
pooled, concentrated, and dialyzed overnight against 4 L of Buffer A and stored at -80 °C. 
Protein concentration was determined using the Bradford reagent (BioRad) with BSA as a 
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standard. The CBpPRF, the C314S mutant and the isolated rhodanese domain were purified 
using the same protocol. 
3.3.4. Metal analysis 
 Plasma emission spectroscopy was used to analyze the total metal content of wild-type 
BpPRF at the Chemical Analysis Laboratory (University of Georgia, Athens). Twenty metal ions 
are detected by this method. The iron content of the enzyme was also measured using a 
colorimetric assay described previously (32). This method allows for the direct measurement of 
total iron content, the Fe(II) content and consequently, estimation of the Fe(III) content of the 
enzyme. Briefly, BpPRF (10-50 µM) was denatured with 0.5 N HCl and 5% (w/v) trichloroacetic 
acid (final volume 1 mL), mixed for 30 s and subsequently centrifuged for 10 min at 16,000  g 
in a microcentrifuge. To determine the total iron content, the supernatant (700 µL) was mixed 
with 300 L of a 1:2:1 mixture of 4 mM 2,4,6-tripyridyl-S-triazine, 50 % ammonium acetate, 
and 10 % hydroxylamine chloride, and incubated at room temperature for 5 min. Hydroxylamine 
was present to reduce residual Fe(III) to Fe(II). Absorbance of the resulting Fe(II)-2,4,6-
tripyridyl-S-triazine complex was measured at 569 nm.  The total Fe concentration was 




 for the Fe(II)-2,4,6-tripyridyl-S-
triazine complex (32).   
3.3.5. Molecular mass determination 
 Purified BpPRF (5 ml of 3.7 mg/ml) was loaded onto a HiLoad™ 16/60 Superdex G-200 
column equilibrated with Buffer A at 4 °C and calibrated with protein standards (Bio-Rad). The 
protein was eluted at a flow rate of 0.5 mL min
-1
 and was monitored by absorbance at 280 nm.  
3.3.6. Thermal denaturation assay 
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 The thermal stability of BpPRF and of the C314S rhodanese domain mutant was 
evaluated by monitoring the increase in absorbance at 600 nm with increasing temperature. For 
this, enzyme (100 g) in Buffer A (final volume 200 l) was placed in a cuvette housed in a 
Cary 100 Bio spectrophotometer equipped with a heating block connected to a water bath. The 
temperature was increased from 25-70 °C in 5 °C increments.  
3.3.7. Preparation of GSSH 
 GSSH was prepared anaerobically as described previously (14) by reacting oxidized 
glutathione (GSSG) with Na2S in a Coy anaerobic chamber  (atmosphere of 95:5 N2:H2) (Eq. 
3.4).  
 GSSG + Na2S  GSSH + GSH    [3.4] 
Briefly, solid Na2S was added in 4-fold excess, to an anaerobic solution of 50 mM GSSG in 350 
mM sodium phosphate, pH 7.4 (final volume 5 mL). The reaction vial was immediately sealed to 
prevent loss of Na2S and incubated at 37 °C for 25-30 min. The concentration of GSSH was 
measured using the cold cyanolysis method as described previously (14). Substrate was either 
used immediately or stored at -20 °C until use. Substrate concentration was measured both 
before freezing and after thawing prior to use in the enzyme assay. Cysteine persulfide was 
prepared using the same procedure. 
3.3.8. Oxygen consumption assay 
 The PDO activity of BpPRF was measured by monitoring O2 consumption at room 
temperature (22 ˚C). The reaction mixture consisted of 100 mM sodium phosphate, pH 7.4, and 
0.5-2 g of enzyme (final volume 1.6 mL) mixed in a Gilson-type chamber containing a Clark 
oxygen electrode and a magnetic stir bar. The reaction was initiated by addition of GSSH (0.02-3 
mM). The effects of GSH, Na2S, sulfite and thiosulfate on the PDO activity were assessed at 5 
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mM concentrations of each except for sulfite, which was added to a final concentration of 0.6 
mM. Cysteine persulfide was tested as an alternative substrate at a final concentration of 1 mM. 
The dependence of reaction velocity on O2 concentration was determined as follows. The 
complete reaction mixture containing enzyme, the substrate GSSH and 100 mM phosphate pH 
7.4 was prepared anaerobically in an inflatable glove chamber,  Glove-Bag™ (Cole-Palmer), 
filled with nitrogen (concentration > 99%) and the reaction was started by injecting buffer with a 
known concentration of dissolved oxygen O2 (generated using a 100% oxygen tank) to give the 
final O2 concentrations ranging from 1.6-250 M. O2 concentration in oxygenated buffer was 
independently determined using the oxygen probe. 
3.3.9. Thiosulfate:cyanide sulfurtransferase assay 
 The cyanide detoxification activity of BpPRF was measured in a colorimetric assay as 
described previously (33). The reaction mixture contained 60 mM thiosulfate, 60 mM potassium 
cyanide and 5-10 µg protein in 200 mM sodium phosphate buffer, pH 7.4 (330 µL final volume). 
The reaction was initiated by addition of enzyme. After incubation for 20 min at 22 ˚C, the 
reaction was stopped by addition of 100 L of 15 % (w/v) formaldehyde. Thiocyanate formation 
was measured by addition of 500 L of a ferric nitrate solution containing 165 mM ferric nitrate 
nonahydrate and 13.3% (v/v) nitric acid. The absorbance of the resulting ferric thiocyanate 
complex was measured at 460 nm. The concentration of thiocyanate formed was determined 
using a standard curve. The concentrations of cyanide and thiosulfate were varied from 0.5-60 
mM to determine the dependence of enzyme activity on substrate concentration.  
3.3.10. Thiosulfate:GSH sulfurtransferase activity monitored in a coupled assay 
 The GSSH formed via the sulfur transfer activity of BpPRF was measured by coupling to 





thiosulfate, 30 mM GSH, 25-30 g enzyme and 200 mM sodium phosphate 
buffer, pH 7.4 (final volume 1.6 mL) mixed in a Gilson-type chamber containing a Clark oxygen 
electrode at 22 °C. GSH and thiosulfate concentrations were varied from 0.3-30 mM to 
determine the dependence of enzyme activity on substrate concentration.  
3.3.11. Thiosulfate:GSH sulfurtransferase activity monitored by sulfite formation 
 The thiosulfate:GSH sulfurtransferase activity of BpPRF and of the isolated rhodanese 
domain was monitored by detecting sulfite formation using a modified version of the 
colorimetric assay described previously (34). The reaction mixture contained 45 mM thiosulfate, 
45 mM GSH, 0.7-3 g enzyme and 200 mM sodium phosphate buffer, pH 7.4 (final volume of 
500 L). The reaction was initiated by addition of enzyme. After 5 min of incubation at 22 ˚C, 
the reaction was stopped by the addition of 500 L of 0.23 M HgCl2. After centrifugation at 
16,000  g, for 1 min, the supernatant (125 lL) was mixed with 1 ml of a p-rosaniline solution 
containing 2:1 0.04% p-rosaniline prepared in 0.72 M HCl (w/v):0.2% formaldehyde. The 
absorbance of the resulting p-rosaniline sulfonic acid complex was measured at 570 nm. The 
concentration of sulfite
 
formed was determined using a standard curve. The concentrations of 
thiosulfate and GSH were varied from 0.3-50 mM to determine the dependence of enzyme 
activity on substrate concentration.  
3.3.12. Thiosulfate:thiol sulfurtransferase activity monitored by H2S formation 
 The sulfurtransfer activities of  BpPRF and of the isolated rhodanese domain was 
measured by detecting H2S formation using the lead acetate assay described previously (18). The 
reaction mixture contained thiosulfate (0.5-25 mM) and either GSH (2-40 mM) or cysteine (1-50 
mM) in 200 mM sodium phosphate buffer, pH 7.4 (final volume of 1 mL) and was pre-incubated 
at 37 °C for 10 min. The reaction was initiated by addition of 0.7-15 g enzyme. Formation of 
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lead sulfide was measured at 390 nm and the concentration of H2S formed was calculated using 




for lead sulfide (18)  
3.3.13. GSSH:sulfite sulfurtransferase actvity 
 The reactions were performed in a Coy anaerobic chamber to prevent oxidation of GSSH 
by the PDO domain. The standard reaction mixture contained 1 mM GSSH and 1 mM sulfite, 
0.5-50 g enzyme, and 20 mM sodium phosphate buffer, pH 7.4 (200 L final volume). The 
derivatization reaction was initiated by the addition of enzyme. After 5 min of incubation, 
monobromobimane was added to a final concentration of 3 mM and incubated at room 
temperature for 15 min. The derivatization reaction was terminated by addition of 100 L of 0.2 
M sodium citrate, pH 2.0. Production of thiosulfate from GSSH and sulfite was monitored by 
HPLC. For this, a 60 mM stock solution of monobromobimane was prepared in DMSO and 
protected from light during preparation and handling. Bimane adducts of GSSH, Na2S, GSH, 
sulfite, and thiosulfate, were prepared in 20 mM sodium phosphate, pH 7.4. Each standard (final 
concentration 250 M) was incubated with a final concentration of 3 mM monobromobimane 
(200 l final volume) for 10 min at 22 ˚C.  
 The derivatized samples were centrifuged at 10,000 × g for 10 min at 4 °C, and the 
supernatants were separated on a 4.6  150 cm C18 reverse phase HPLC column (3 M packing, 
SunFire) using an Agilent 1100 series HPLC system equipped with a multi-signal fluorescence 
detector.  The column was equilibrated with the following solution: 80 % solvent A (897.5 mL 
water, 100 mL methanol, and 2.5 mL acetic acid) and 20 % solvent B (97.5 mL water, 900 mL 
methanol, and 2.5 mL acetic acid). Samples (50 L) were injected onto the column and resolved 
using the following gradient of solvent B: 20 % from 0-5 min, 20-45 % from 5-10 min, 45 % 
isocratic from 10-15 min, 45-50 % from 15-25 min, 50 % isocratic from 25-28 min, 50-100 % 
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from 28-30 min, 100 % isocratic from 30-39 min, 100-20 % from 39-42 min, 20 % isocratic 
from 42-48 min. The flow rate was 0.75 min/mL. Fluorescence of the bimane adducts was 
detected using 340 nm excitation and 450 nm emission. The concentration of thiosulfate was 
determined using the peak areas and a standard curve.  
3.3.14. Stoichiometry of O2 consumption and sulfite formation 
 The stoichiometry of coupling between the PDO and rhodanese active sites was 
monitored using wild-type and C314S BpPRF as follows. The reaction mixture contained 1 mM 
GSSH, 75 nM enzyme, and 200 mM sodium phosphate buffer, pH 7.4 (1.6 ml final volume) in a 
Gilson-type chamber containing a Clark oxygen electrode. The reaction was initiated by addition 
of GSSH and O2 consumption was recorded. After 5 min at 22 °C, an aliquot of the reaction mix 
(50 l) was added to 60 mM monobromobimane (20 l) to a final concentration of 17 mM. After 
incubation for 15 min at room temperature, the reaction was quenched with 100 l of 0.2 M 
sodium citrate, pH 2.0. The derivatized samples were processed and separated by HPLC as 
described above to determine concentrations of sulfite formed and thiosulfate consumed 
3.3.15. Reaction stoichiometry under single and multiple turnover conditions 
 The reaction stoichiometry of wild-type and C314S BpPRF under single turnover 
conditions was monitored as described above with the following variation. The reaction mixture 
contained 250 M thiosulfate, 250 M GSH, and varying concentrations of enzyme (250, 125, 
83, 62.5, 50 and 42 M). The reaction was initiated by addition of GSH. After incubation for 30 
min at 22 °C, an aliquot of the reaction mix (50 L) was mixed with 20 µL of 60 mM 
monobromobimane and processed as described above. For analysis of the reaction stoichiometry 
under single turnover conditions in the absence of O2, the enzymatic assay and derivatization 
reactions were performed in a Coy anaerobic chamber (atmosphere of 95:5 N2:H2).  
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3.3.16. Protein crystallization 
 The C-terminal truncated BpPRF ( CBpPRF) and C314S BpPRF were crystallized by 
sitting drop vapor diffusion using 0.75 L:0.75 L protein stock:well solution. CBpPRF (5 
mg/mL in 50 mM Tris, pH 8, 0.25 M NaCl, 10 % glycerol, 5 mM thiosulfate) crystallized in 3 
days at 20 °C in the following conditions: 0.2 M zinc acetate, 0.1 M MES, pH 6, 10 % PEG-
8000. A single rhombohedral rod-shaped crystal was harvested directly from the drop without 
cryoprotection and flash-cooled in liquid nitrogen. C314S BpPRF (5 mg/mL in 50 mM Tris, pH 
8.0, 0.25 M NaCl, 10% glycerol) crystallized in 2 days in the following conditions: (0.12 M 
NaCl, 0.1 M imidazole, pH 8.0, 25 % PEG-8000). To obtain structural data for C314S BpPRF in 
complex with GSH, 5 mM GSH was added to the drop overnight. The hexagonal rod-shaped 
crystals were cryo-protected by passing harvested crystals through 2 L of reservoir solution 
with an additional 15% glycerol followed by flash cooling with liquid nitrogen. 
3.3.17. Data collection and crystal structure determination 
 Diffraction data were collected at the Advanced  Photon Source (APS, Argonne National 
Laboratory) on the GM/CA beamline 23ID-D or 23ID-B (Table 3.1). For CBpPRF, data were 
collected on a single crystal to 1.79 Å resolution. For the apo- and GSH-soaked C314S BpPRF 
crystals, data were collected to 2.49 and 2.09 Å, respectively. All data were processed using 
XDS (35). The truncated structure was solved by molecular replacement using BALBES (36) 
with the AaPRF (PDB ID: 3TP9) as a search model. Phenix AUTOBUILD was used to build an 
~70 % complete model. To complete the model, consecutive rounds of model building and 
refinement were performed using Coot (37) and PHENIX (38). The structures were validated 
using MolProbity (39). Electron density is complete for all BpPRF residues except for eight in 
the linker region between the PDO and rhodanese domains and the N-terminal histidine tag. 
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TABLE 1. X-ray data collection and refinement statistics 
 
1
Values in parentheses pertain to the outermost shell of data. 
2












Space group P212121 P6522 P6522 
Cell dimensions    
a,b,c (Å) 63.7, 108.3, 119.6 84.5, 84.5, 549.4 83.5, 83.5, 547.6 
α, β, γ (°) 90, 90, 90 90, 90, 120 90, 90, 120 
X-ray Source APS 23ID-D APS 23ID-B APS 23ID-B 
Wavelength (Å) 1.033 1.033 1.033 
dmin (Å) 1.79 (1.86-1.79)
1








0.047 (7.8 Å) 
0.126 (1.56) 
0.050 (7.0 Å) 
Avg I/σ(I) 14.6 (1.2) 11.6 (1.7) 11.0 (1.6) 
Completeness (%) 100 (96.0) 100 (100) 99.0 (99.0) 
Multiplicity 12.4 (9.0) 8.6 (8.5) 8.7 (9.2) 






CC1/2 0.999 (0.537) 0.997 (0.898) 0.998 (0.904) 
CC* 1.0 (0.836) 0.999 (0.973) 0.999 (0.975) 
Refinement    
Data range (Å) 41.26-1.79 43.94-2.65 41.75-2.35 
Reflections used in refinement 77,982 (7,448) 35,305 (3,392) 48,680 (4,773) 
Rwork/Rfree (%) 16.1/19.6 23.2/26.7 19.7/25.2 
Number of non-hydrogen atoms 6051 8265 8471 
  protein 5538 8153 8154 
  ligands 2 24  74 
  water 511 88 189 
Amino acid residues 698 1047 1048 
Deviation from ideality    
bond lengths (Å) 0.013 0.003 0.007 
bond angles (°) 1.20 0.70 0.97 
Average B-factor 38.1 81.9  76.6 
  macromolecules 37.6 82.4  77.0 
  ligands 29.6 59.0  83.1 
  solvent 44.1 45.6  58.4 
Ramachandran plot    
  favored (%) 98.0 96.0 97.5 
  allowed (%) 2.0 4.0 2.3 
  outliers (%) 0 0 0.2 
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The C314S structure was solved via molecular replacement using Phaser within the Phenix 
software suite with the complete truncated model as a search model. Molecular replacement 
successfully placed two copies of the chain and the third was added in manually using Coot. 
Notably, a chloride ion sits in the place of the C314 persulfide in the C314S structure. The GSH-
bound structure was solved via rigid body refinement in Phenix Refine. Electrostatic surface 
potentials were calculated using the APBS program in PYMOL (40-42). Figures were prepared 
using PYMOL(43). Authors N.M. and M.S. solved the crystal structures.  
3.4. Results 
3.4.1. Purification and properties of BpPRF 
 Recombinant wild-type and variants of BpPRF purified using a one-step protocol were 
obtained in >95% purity as judged by SDS PAGE analysis (not shown). The yield for the full-
length proteins (wild-type and C314S), was ~120 mg protein per liter of culture. The rhodanese 
domain was obtained with a yield of 22 mg of protein per liter of culture. BpPRF eluted from a 
size exclusion column with a molecular mass corresponding to 40 kDa, consistent with it being a 
monomer (predicted mass = 41.5 kDa). The rhodanese domain eluted as a mixture of a monomer 
and a dimer (not shown). The monomeric organization of BpPRF is distinct from that of CstB, 
which is tetrameric (23). 
 The thermal stability of the BpPRF variants was assessed in a turbidometric assay. The 
Tm value for the isolated rhodanese domain (55 ± 2 °C) was slightly higher than for wild-type (50 
± 2 °C) and C314S (51.6 ± 0.8 °C) BpPRF. This result indicates that the stand-alone rhodanese 
domain is well folded and contrasts with the instability of the catalytic rhodanese domain of 
CstB when it was expressed by itself (23).   
3.4.2. Metal Analysis 
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 Plasma emission spectroscopy revealed the presence of 0.54 ± 0.07 mol iron/mol 
monomer wild-type BpPRF. The metal content was also assessed by a colorimetric assay (32), 
which yielded a similar value (0.60 ± 0.03  mol iron/mol monomer). The iron content of C314S 
BpPRF was 0.46 ± 0.02 mol iron/mol monomer (Table 3.2). Attempts to fully reconstitute the 
metal site with FeCl2 under anaerobic conditions were unsuccessful. 
3.4.3. Structure of BpPRF 
 The crystal structure of BpPRF co-crystallized with thiosulfate, was obtained at 1.79 Å 
resolution by molecular replacement using the AaPRF structure (PDB 3TP9) as template (Table 
3.1). The final model contains two chains representing a crystallographic dimer in the 
asymmetrical unit. Each monomer consists of an N-terminal PDO domain (residues 1-230), a 15-
residue linker (residues 231-245), and a C-terminal rhodanese domain (residues 246-357) (Fig. 
3.2A). The PDO domain displays a typical metallo- -lactamase-type fold consisting of two 
central -sheets enclosed by three helices on each side (15,29,44). Density for eight of the fifteen 
residues in the linker region was missing, indicating that it is disordered (Fig. 3.2A). The C-
terminal domain displays a characteristic rhodanese fold with a five stranded parallel -sheet 
core framed by two -helices on one side and three -helices on the other side of the domain 
(45). Additionally, a -hairpin extension is seen on the N-terminal side of the rhodanese domain 
(Fig. 3.2A). The two active sites are located at different ends of the protein, separated by a 
rotation angle of ~90° (Fig. 3.3A). 
 The PDO domain active site contains a mononuclear non-heme iron coordinated by 
His58, His114 and Asp133 comprising a 2His:1Asp facial triad. The remaining coordination 
sites are occupied by water molecules, which complete an octrahedral geometry around the 
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ferrous iron (Fig. 3.2B). Cys314 located in the rhodanese active site, was captured in its 
persulfidated, Cys-SSH  
 
 
Figure 3. 2. Crystal structure of BpPRF. The X-ray crystal structure of CBpPRF was solved 
at 1.79 Å resolution by molecular replacement using the AaPRF structure (PDB ID: 3TP9) as a 
template. A, The structure of the BpPRF monomer consists of an N-terminal PDO domain (blue), 
a fifteen residue linker region (orange) and a C-terminal rhodanese domain (red). The linker 
region lacked density for eight residues (dashed lines) suggesting a flexible, disordered state. The 
iron is shown as an orange sphere and ligands in the PDO domain and the active site cysteine, 
Cys314, in the rhodanese domain are shown in stick representation. The rhodanese domain -
hairpin extension is highlighted by the black arrow. B, close-up of the PDO active site with 
representative electron density (3.0  Fo-Fc omit density in grey mesh) for side chains of His58, 
His114, Asp133 and three water molecules (shown as red spheres) coordinated to the iron center 
(orange sphere). C, Close-up of the rhodanese domain active site with representative electron 
density (3.0  Fo-Fc omit density in grey mesh) for the Cys314 side chain displaying the 
additional density for the persulfide modification.  
 
form (Fig. 3.2C). The PDO active site is located at the bottom of a large pocket (Fig. 3.3A) 
framed on one side by a positively charged ridge comprising residues Arg193-Lys216 and by 
Tyr176 on the other (Fig. 3.3B). The rhodanese active site is located at the bottom of a shallow 
pocket that is lined by the positively charged residues, Arg315 and Arg319 on one side, and 





Figure 3.3. Surface represenation of BpPRF active sites. A, Surface representation of BpPRF 
displaying the PDO and rhodanese domain active site pockets located on different faces of the 
enzyme. The PDO domain iron is displayed as an orange sphere. The iron ligands and the 
catalytic cysteine are labeled. B, Close-up of the electrostatic surface around the PDO domain 
active site. The positively charged ridge of the active site contributed by residues Arg193-
Lys216 and the polar Tyr176 frame the active site pocket and may play a role in substrate 
binding. C, close upof the rhodanese domain showning a mostly positive electrostatic surface 
potential . The active site cysteine is framed by positively charged and hydrophobic residues 
(Arg315, Ala316, Gly317, Gly318, Arg319). In B and C, blue and red denote positive and 




 C314S BpPRF crystallized in a different space group (Table 3.1) but in the same 
conformation as wild-type BpPRF. Crystals of C314S BpPRF that had been soaked with GSH, 
displayed additional density in two of the three chains present in the asymmetric unit. GSH 
coordinates to iron in the PDO active site and displaces one of the iron-coordinated waters. It is 
within hydrogen bonding distance of Tyr176, Arg193, Arg142 and Lys216 (Fig.  3.4A). 
 
Figure 3.4. Close up of the PDO active site of BpPRF with GSH. A, Stereo view of the C314S 
BpPRF PDO domain with GSH bound. The surrounding residues that may participate in 
substrate binding and/or stabilization are shown with electron density (3.0  Fo-Fc omit density 
in grey mesh) for GSH. Tyr176, Arg142, and Lys216 are hydrogen bonded (black dashes) to 
GSH. Two waters (red spheres) are coordinated to the iron center (orange sphere) in addition to 
the sulfur atom of GSH. B, Stereo veiw of C314S BpPRF PDO domain (blue) in complex with 
GSH overlaid on human PDO (15) (PDB ID: 4CHL) (grey). GSH (shown in magenta) is 
displyed in stick representation. Conserved residues predicted to be involved in substrate 
binding, stabilization and/or positioning are Ty176, Arg193, Leu212, Arg142 and Pro215 





Figure 3.5. Comparison of the BpPRF rhodanese domain with bovine rhodanese. A, 
Structural overlay of the BpPRF rhodanese domain (red) with the catalytic domain of bovine 
rhodanese (PDB ID: 1RHD) (grey). The active site cysteine residues, C247 (bovine) and C314 
(BpPRF) are shown in stick representation A -hairpin extension seen only in BpPRF is 
highlighted by a red arrow. Two loop extensions seen only in bovide rhodanese, are highlighted 
by black arrows. B, structural overlay of the rhodanese active site loops from BpPRF (red) and 
bovine rhodanese (grey).  
 
 
3.4.4. Structural comparisons between BpPRF and homologous human proteins 
 The architecture of the BpPRF PDO active site is very similar to that of human PDO (Fig. 
3.4B). The substrate-binding pocket is framed by two -helices on one side and by Tyr176 on 
the other. Key residues that are predicted to be involved in substrate binding in human PDO, 
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Tyr197, Arg214, Arg163, Leu231 and Pro234 are conserved in BpPRF (Tyr176, Arg193, 
Arg142, Leu212 and Pro215) and are found in similar orientations. Lys216, which is not 
conserved in human PDO, lines the entrance to the active site and might play a role in substrate 
positioning.  
 The BpPRF rhodanese domain and the catalytic domain of bovine rhodanese display very 
similar folds (Fig. 3.5A). Minor structural differences include the N-terminal -hairpin extension 
in BpPRF and two extra loops in bovine rhodanese. The active sites are also very similar with the 
conserved residues, Cys314, Arg315 and Gly318 (BpPRF numbering), being in similar 
orientations (Fig. 3.5B). However, Thr252 and Lys249 in bovine rhodanese occupy the same 
positions as Arg319 and Ala316, respectively, in BpPRF. These substitutions indicate differences 
in charge distribution that might contribute to differences in substrate specificity. 
3.4.5. PDO activity of BpPRF 
 The rate of O2 consumption during conversion of GSSH to sulfite (Eq. 3.3) was 
monitored using an O2 electrode (Fig. 3.6 and yielded the following kinetic parameters for wild-
type BpPRF: Km(GSSH) = 70 ± 8 M, and Km(O2) = 130 ± 30  M and kcat = 143 s
-1
 at 22 ˚C, (Table 
3.2). C314S BpPRF exhibited a 29-fold lower kcat and an ~5-fold higher Km for GSSH than wild-
type BpPRF. Addition of 2.5 mM ascorbate to the standard assay resulted in an ~20% increase in 
the PDO specific activity (not shown). Cysteine persulfide and thiosulfate were also tested as 
potential substrates for the PDO domain.  However, neither displayed detectable activity. 
 It is important to note that the method used to synthesize GSSH results in its 
contamination with an equal concentration of GSH and an ~3-fold excess of H2S, as described 
previously (14). The potential effects of GSH and sulfide on PDO activity was examined in 
addition to the effect of sulfite (a PDO product) and thiosulfate (rhodanese substrate/product)  
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(Table 3.3). Sulfite, which consumed O2, increased the background rate and was therefore used 
at a lower concentration (0.6 mM) than the other metabolites (5 mM each). GSH was slightly 
activating (1.3-fold increase in kcat/Km(GSSH)) as seen previously with human PDO (14).  
Thiosulfate was without effect, while H2S and sulfite decreased kcat/Km(GSSH) 1.6- and 2.2-fold.  
 
Figure 3.6. Kinetics of PDO activity of BpPRF. Dependence of PDO activity on GSSH 
concentration for wild-type BpPRF (solid circles) and C314S BpPRF (open circles). Oxygen 
consumption by BpPRF in 100 mM sodium phosphate buffer, pH 7.4, was monitored at 22 ˚C in 



















The kinetic parameters were determined by monitoring O2 consumption in the presence of 
GSSH at 22 ˚C and pH 7.4, as described under Experimental Procedures.  
 
 
















None 207 ± 6 0.070 ± 0.08 143 2043 
5 mM GSH 410 ± 8 0.103 ± 0.007 283 2748 
5 mM S2O3
2-
 302 ± 18 0.12 ± 0.02 209 1742 
5 mM Na2S 186 ± 10 0.10 ± 0.01 127 1270 
0.6 mM SO3
2-
 232 ± 10 0.17 ± 0.03 160 941 
a
The kinetic parameters were determined by monitoring O2 consumption in the presence of 
GSSH as described under Experimental Procedures.  
 
3.4.6. Sulfurtransferase activity of BpPRF 
 Conversion of cyanide to thiocyanate in the presence of thiosulfate (Eq. 3.5) was used to 









  [3.5] 
Km(thiosulfate) of 5.4± 0.7 mM, Km(CN-) of 22.7 ± 0.7 mM and kcat of 5.1 s
-1
  at 22 ˚C were obtained 
(Table 3.4). Under the same conditions, the sulfurtransferase activity of the C314S mutant, 
carrying an inactivating mutation in the rhodanese domain, was not detectable (data not shown).  
 Since GSSH, a product of the sulfurtransferase reaction (Eq. 3.2), is a substrate for the 
PDO domain (Eq. 3.3), this activity was monitored in a “coupled” assay, i.e. by detecting O2 
Enzyme Iron 
Content 





















Wild type 0.60 ± 0.03 207 ± 6 0.070 ± 0.008 0.13 ± 0.03 143 2043 1100 
C314S 0.46 ± 0.02 7.3 ± 0.1 0.37 ± 0.04 --- 5 14 --- 
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consumption (Figs. 3. 7C and 3.8C). This assay yielded the following parameters: Km(GSH) = 4.7 
± 0.7 mM, Km(thiosulfate)  = 3.1 ± 0.2 mM and kcat = 6.2  s
-1 
(Table 3). The same reaction was also 
monitored directly, i.e. by detecting sulfite (Eq. 3.2) colorimetrically, and yielded essentially the 
same results (not shown).  
 Cysteine was tested as an alternate sulfur acceptor in lieu of GSH, by monitoring H2S 
production using the lead sulfide assay (Eqs. 3.6 and 3.7) (Figs.3.7E and 3.8E).  
 S2O3
2-
 + Cys-SH  SO3
2-
 + Cys-SSH  [3.6] 
 Cys-SSH + Cys-SH  Cys-S-S-Cys + H2S  [3.7]  
This analysis yielded the following values: Km(Cys) = 5.2 ± 0.4 mM, Km(thiosulfate)  = 5.8 ± 0.8 mM 
and kcat = 0.2  s
-1
. Given the relatively low cellular concentration of cysteine versus GSH and the 
considerably lower kcat/Km(cys) value (Table 3.4), cysteine is unlikely to be a physiologically 
relevant sulfur acceptor for BpPRF.  
 Next, we attempted to monitor sulfurtransferase activity in the opposite direction (i.e. 
reverse of Eq. 3.2) by tracking thiosulfate formation under anaerobic conditions (to inhibit GSSH 
consumption by PDO). However, unlike human rhodanese (18,20), sulfur transfer activity from 














TABLE 3.4. Kinetic parameters for the sulfurtransferase activity of BpPRF
c
 



























 7.4 ± 0.3 5.4 ± 0.7 22.7 ± 0.7 5.1 0.9 0.2 
2. GSSH SO3
2-
 nd nd nd nd nd nd 
3. S2O3
2-
 GSH 8.9 ± 0.2 3.1 ± 0.2 4.7 ± 0.4 6.2 2.0 1.3 
4. S2O3
2-
 Cys 0.32 ± 0.01 5.8 ± 0.8 5.2 ± 0.4 0.2 0.04 0.04 
c
The kinetic parameters for the sulfur transfer reactions 1-4 were determined at pH 7.4 as 
follows. Reaction 1 monitored thiocyanate formation (22 ˚C), Reaction 2, monitored thiosulfate 
formation (22 ˚C), Reaction 3, monitored sulfite formation (at 22 ˚C), or GSSH formation (via 
O2 consumption in the coupled PDO reaction at 22 ˚C), or H2S formation (37 ˚C), and Reaction 
4, monitored H2S formation (37 ˚C), as described in the Experimental Procedures. 
 
 
TABLE 3.5. Kinetic parameters for the isolated rhodanese domain of BpPRF
d
 



























 18 ± 1 9.2 ± 0.8 23 ± 1 4.6 0.5 0.2 
GSSH SO3
2-
 nd nd nd nd nd nd 
S2O3
2-
 GSH 35 ± 2 3.8 ± 0.5 14.9 ± 0.5 9.0 2.3 0.6 
S2O3
2-
 Cys 3.1 ± 0.1 6.1 ± 0.4 5.4 ± 0.3 0.8 0.1 0.1 
d
The kinetic parameters of the sulfur transfer reactions catalyzed by the isolated rhodanese 







Figure 3.7. Kinetics of BpPRF-catalyzed sulfur transfer reactions. The sulfurtransferase 
activity associated with the rhodanese domain in wild-type BpPRF (A, C, E) or with the isolated 
rhodanese domain (Rhod domain) (B, D, F) was determined in the presence of a constant 
thiosulfate concentration (60 mM) and varying concentrations of cyanide (A and B), GSH, (C 
and D) or cysteine (E and F). The data are representative of 3-4 independent experiments. The 







Figure 3.8. Kinetics of BpPRF-catalyzed sulfur transfer reactions. Dependence of 
sulfurtransferase activty on varying thiosulfate concentrations in the presence of 60 mM cyanide 
(A and B), 30 mM GSH (C and D), and 50 mM cysteine (E and F) for wild-type BpPRF and the 
isolated rhodanese domain (Rhod Domain). The reactions were performed as described under 
Experimental Procedures. The data are representative of 3-4 independent experiments.  Data 
were fitted with either the Michaelis Menten or sigmoidal equation. 
 
3.4.7. Sulfurtransferase activity of the rhodanese domain 
 The isolated rhodanese domain is active and exhibits the following kinetic parameters in 
the cyanide detoxification assay (Fig. 3.7B, 3.8B): Km(thiosulfate) = 9.2 ±  0.8 mM and Km(CN
-
) = 23 
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± 1 mM, kcat = 4.6  s
-1 
(Table 4), which are very similar to those for full-length  BpPRF. GSSH 
synthesis from thiosulfate and GSH (Eq. 3.2) was monitored by following H2S formation (Eq. 
3.8) (Fig. 3.7D and 3.8D). 
 GSSH + GSH  GSSG + H2S  [3.8] 
The following values were obtained from this analysis: Km(GSH) = 14.9  ± 0.5 mM and a 
Km(thiosulfate) = 3.8 ± 0.5 mM  and kcat = 9.0  s
-1
. As with the full-length protein, cysteine was a 
poor acceptor (6-fold lower kcat/Km than GSH (Fig. 3.7F and 3.8F) and the reverse reaction (i.e. 
transfer from GSSH to sulfite) was not detectable (Table 3.5). Similar values for the kinetic 
parameters were obtained when the rate of sulfite production was detected (data not shown). 
3.4.8. Stoichiometry of PRF reaction 
 Our kinetic data predicts that BpPRF can catalyze a GSH dependent net oxidation of 
thiosulfate to sulfite (Eqs. 3.2 and 3.3). To verify this prediction, the stoichiometry of thiosulfate 
and O2 consumed to sulfite formed was determined. As noted previously, the method used to 
synthesize GSSH results in an equivalent of GSH being present, which together with unreacted 
GSSG and an ~3-fold excess of H2S, would confound the reaction stoichiometry. To circumvent 
this problem, GSSH was synthesized in situ using GSH and thiosulfate as substrates (Eq. 3.2). 
 Under single turnover conditions, the stoichiometry of sulfite formed/thiosulfate 
consumed/oxygen consumed was 2:1:1 (Fig. 3.9A) as predicted by Eqs. 3.2 and 3.3. Also, as 
expected, the reaction stoichiometry of sulfite formed/GSH consumed/thiosulfate consumed was 









Figure 3.9. Product analysis and reaction stoichiometry of the BpPRF-The reaction 
stoichiometry of BpPRF under single turnover conditions was analyzed in the presence (A) and 
absence (B) of oxygen. The reactions were performed in the presence of 250 M GSH, 250 M 
thiosulfate and 250 M enzyme. C, The stoichiometry of BpPRF reactions under multiple 
turnover conditions was analyzed in the presence of 250 M GSH, 250 M thiosulfate and 
decreasing enzyme concentrations as described under Experimental Procedures. 
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However, when the BpPRF reaction was monitored under multiple turnover conditions in 
the presence oxygen, the stoichiometry of sulfite formed/thiosulfate consumed/oxygen consumed 
switched to 1:1:1 after three turnovers (Fig. 3.9C). This change in stoichiometry indicates 
inefficient coupling between the PDO and rhodanese active sites, and is likely confounded by 
side reactions of the reactive products, particularly GSSH (46), as it builds up under these 
conditions. 
3.5 Discussion 
 Natural fusions of PDO and rhodanese are found in bacteria and suggest a functional 
interaction between them in other organisms, where they are expressed as stand-alone proteins 
(47). In this study, we provide the first structural and kinetic characterization of a PRF. To our 
knowledge, the only other PRF that has been biochemically characterized is CstB from S. aureus 
(23,30,48), but the available CstB structure is missing density for the catalytic rhodanese 
domain. CstB is located in the cst operon (Fig. 3.1C). Its operonic partners include CstA, which 
is a rhodanese, and a sulfide quinone oxidoreductase, which oxidizes H2S to polysulfides (30). 
Expression of the cst operon is regulated by the persulfide/polysulfide-sensing repressor CstR 
and is induced by exogenous addition of H2S or polysulfides (49). CstB catalyzes the conversion 
of low molecular weight persulfides to thiosulfate via the intermediate formation of sulfite (Eq. 
3.9) (23). In contrast to CstB, BpPRF preferentially catalyzes sulfur transfer in the reverse  




 + 2RSH + 2H
+   
[3.9] 
direction, i.e. from thiosulfate to sulfite (Eq. 3.10), which was confirmed under single turnover 
conditions (Fig. 3.8). 
 S2O3
2-






   [3.10] 
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 GSSH serves as the intermediate sulfur carrier in the BpPRF reaction, transferring sulfur 
processed in the rhodanese active site to the PDO active site. Unlike CstB, which functions in the 
sulfide stress response, the cellular context in which BpPRF functions, is not known (49). Since 
the gene encoding BpPRF does not reside in an operon, the metabolic context in which it 
functions is not immediately obvious. The BpPRF-encoding gene is located downstream from a 
putative peroxidase and a putative LysR-type regulator, which have been shown to be involved 
in regulating bacteria mobility, virulence, metabolism and quorum sensing (50) (Fig. 3.1C). A 
potential fate of sulfite, which is toxic, is its oxidation by sulfite oxidase to sulfate, which could 
be utilized in an assimilatory sulfate-reducing pathway. B. phytofirmans encodes a putative 
sulfite oxidase. Alternatively, BpPRF might be involved in sulfur assimilation from thiosulfate 
and sulfite could be reduced by sulfite reductase (encoded by B. phytofirmans) to H2S, which in 
turn is used for cysteine synthesis. In B. cenocepacia, CysB and SsuR regulate genes encoding 
enzymes involved in the aliphatic sulphonate assimilation pathway (25,51). BLAST analysis 
reveals that B. phytofirmans possesses two gene products that have 23 and 26% identity to the 
CysB and SsuR transcriptional regulators, respectively. Bioinformatic analysis of the sequence 
100 base pairs upstream of the BpPRF gene queried against CysB and SsuR binding sites, was 
performed using the FIMO MEME suite database (25,51,52). Several SsuR binding sites (Fig. 
3.10) scored as positive motifs hits in the BpPRF promoter region (p <0.005), consistent with a 








Figure 3.10. Comparison of B. cenocepacia SsuR binding site sequences to the BpPRF 
promoter region. Alignment of BpPRF promoter region with predicted SsuR binding sites that 
displayed high-scoring motif occurrences as assessed by the FIMO MEME suite database (p-
value ≤ 0.005). While there is no obvious consensus sequence in the four promoter regions, 
similarities are observed. Nucleotides conserved in at least three of the four promoter sequences 
are shown in red.  
 






 at 22 ˚C) is 14-fold 






 at 22 ˚C. (14)) and ~10
2
-fold higher than for CstB 






 at 25 ˚C) (23). Mutation of the catalytic 
cysteine residue, C314, in the rhodanese domain decreased iron content 1.3-fold and PDO 
activity, 29-fold. This result is surprising and indicates communication between the rhodanese 
and PDO active sites, which are however distant and oriented 90 ˚ away from each other in the 
crystal structure (Fig. 3.3A). 
 The thiosulfate:cyanide sulfurtransferase activity of BpPRF (kcat = 5.1 s
-1 
at 22 ˚C) is 
comparable to that of CstB (8.5 s
-1
 at 25 ˚C) (23), and 180-730-fold lower than human rhodanese 
(20). The thiosulfate:GSH sulfur transfer activity of BpPRF  (kcat = 6.2 s
-1 
at 37 ˚C) is 9-fold 
higher than for human rhodanese (0.67 s
-1
 at 37 ˚C), which preferentially catalyzes the reaction 
in the reverse GSSH:sulfite sulfur transfer direction (kcat = 389 s
-1 
at 25 ˚C). The isolated 
rhodanese domain was well-folded as evidenced by its high Tm (55 ± 2 °C) versus that of the 
full-length protein (50 ± 2 °C) and its comparable kcat values in the thiosulfate:cyanide and  
thiosulfate:GSH sulfur transfer reactions (Tables 3.4 and 3.5). The isolated rhodanese domain 
exhibits a sigmoidal dependence on GSH and thiosulfate concentration (Fig 3.7D and 3.8D), in 
contrast to the hyperbolic dependence observed with full-length BpPRF (Fig. 3.7C and 3.8C). 
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This difference in behavior could be due to approximately half of the isolated rhodanese domain 
existing as a dimer in solution while the full-length protein is a monomer. Unlike human 
rhodanese, sulfur transfer from GSSH to sulfite was not detectable with either the full-length 
BpPRF or the stand-alone rhodanese domain (Tables 3.4 and 3.5).  
 It is possible that our structure of BpPRF represents an “open” conformation versus a 
“closed” conformation in which the two domains are proximal to each other. We therefore 
attempted to model a putative closed conformation by superimposing the PDO and rhodanese 
domains on the structure of AaPRF. In the latter, the PDO and rhodanese active sites are 
positioned directly across from each other and are separated by a distance of 27 Å (Fig. 3.11A).  
AaPRF contains an additional non-catalytic rhodanese domain and a cysteine-containing loop 
(C202, AaPRF numbering) located in the PDO domain active site. This loop, while absent in 
BpPRF, is also present in CstB and postulated to facilitate substrate transfer between the PDO 
and catalytic rhodanese domains (23). To adopt a similar domain orientation, the 15-amino acid 
residue linker region of BpPRF, which is ~36 Å in length, would have to span 47 Å and possibly 
require the unwinding of a secondary structure element. Furthermore, the electrostatic surface 
potential map reveals that positively charged resides line the entrance to the PDO and rhodanese 
active sites, suggesting that a direct interaction between them would be unfavorable (Fig. 3.11B). 
The structural independence of the active sites is also consistent with the high catalytic activity 
of the isolated rhodanese domain. This result is in contrast to CstB in which the rhodanese 







Figure 3.11. Modeling of potential BpPRF domain interaction interface. A, overlay of 
BpPRF PDO domain (blue) and the BpPRF rhodanese domain (red) with the PDO domain and 
catalyic rhodanese domain of AaPRF (PDB ID: 3TP9) (shown in grey). The active site loop of 
AaPRF with C202 facing the iron center is shown in yellow. The BpPRF active site iron is shown 
as an orange sphere. The N- and C-termini of BpPRF are labeled.  B, Surface electrostatic 
potential of the BpPRF domains in the same orientation as in A but rotated by 35˚. The arrows 
highlight locations of the PDO and rhodanese (Rhod) active sites. Positive and negative electrical 
potential are shown in blue and red, respectively, and represent a range of -5 to +5 kT/e. 
 
 An overlay of five structures, i.e. two per asymmetric unit of wild-type BpPRF and three 
per asymmetric unit of C314S BpPRF, was used to assess significant conformational differences, 
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if any, between them (Fig. 3.12). Since the electron density for eight residues in the linker region 
was missing in these structures, the overlay was used to assess whether the flexible linker might 
allow a closer approach of the rhodanese and PDO domains, permitting a closed conformation. 




Figure 3.12. Overalay of five BpPRF structures shows low conformational variability 
among them. The figure was generated by aligning the PDO domains (residues 1-231) using 
Pymol. The iron in the PDO domain is shown as an orange sphere. The overlay reveals minor 
variations in the position of the rhodanese domain and suggests limited mobility of the 




 In summary, the relative orientation of the two domains in BpPRF and their separation by 
a relatively short linker, suggests that the two active sites do not interact. In fact, the similar 
potential electrostatic surface map also suggests that the active sites are unlikely to interact 
directly. In light of the structural data, it is intriguing that the kinetic data provide some evidence 
for allosteric communication between the domains. For instance, mutation of the catalytic 
cysteine in the rhodanese domain adversely impacts the catalytic properties and to a lesser 
extent, the iron content of the PDO domain. Similarly, isolation of the rhodanese domain, 
improves its kcat. Our kinetic data are consistent with a role for BpPRF in sulfur assimilation 
rather than in a sulfide stress response pathway. 
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 In this chapter the results presented in Chapters II-III are summarized and future 
directions are discussed.  As over 20 PDO mutations have been described in EE patients (1-3), 
we set out to characterize the biochemical penalties associated with a subset of these mutations 
(L55P, T136A, C161Y and R163W). The PDO mutants displayed varying degrees of decreased 
activity and increased Km values for the GSSH substrate. Combined with thermal stability and 
iron content quantification, this study revealed that perturbations of these residues led to 
decreased enzyme stability and activity resulting in loss of PDO function. A previous study 
reported that the R163W and R163Q PDO mutations lowered the iron redox potential (4). It is 
not known whether the three other mutations that we characterized also affected the iron redox 
potential and whether any of them affected the O2 affinity and these properties should be 
assessed in the future.   
The organization of the mitochondrial sulfide oxidation pathway remains in question, and 
future studies should focus on characterizing the interactions between PDO and SQR or 
rhodanese. Both the PDO substrate, GSSH, and the PDO product, sulfite, are reactive. Sulfite is a 
co-substrate for rhodanese, can serve as a sulfane sulfur acceptor for SQR and is a substrate for 
sulfite oxidase (5,6). Understanding the interactions between PDO and SQR or rhodanese might 
provide insights into how the reactivity of the reactive sulfur species formed in the sulfide 
oxidation pathway is controlled.  
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 Next we characterized a bacterial variant of PDO that is fused to a rhodanese domain. 
Characterization of a PRF will facilitate modeling of the interactions between human 
mitochondrial PDO and rhodanese.  We determined the crystal structures and kinetic properties 
of a PDO-rhodanese fusion protein from Burkholderia phytofirmans (BpPRF).   
Our study of the BpPRF rhodanese reactions indicates that the rhodanese domain 
preferentially catalyzes the sulfur transfer from thiosulfate to GSH forming GSSH and sulfite 
(Eq. 4.1). 
 GSH + S2O3
2-
  GSSH + SO3
2-
   [4.1] 
Curiously, BpPRF  does not display detectable sulfur transfer activity in the reverse direction, 
i.e., from GSSH to sulfite forming GSH and thiosulfate (Eq. 4.2).  
 GSSH + SO3
2-
  GSH + S2O3
2-
  [4.2] 
Similar observations have been made in our laboratory for the single-domain sulfur transferase 
TSTD1, which also does not appear to catalyze the sulfur transfer reaction from GSSH to sulfite 
(Eq 4.2) (Libiad and Banerjee, unpublished results). In contrast, human rhodanese, a double-
domain sulfurtransferase catalyzes sulfur transfer depicted in Eq. 4.2 preferentially with a kcat of 
389 s
-1












 compared to a kcat 
of 0.67 s
-1












 for the 
reaction shown in Eq. 4.1 (5). Since GSSH and sulfite are more reactive than GSH and 
thiosulfate, it is expected a priori that the sulfur transfer from GSSH to sulfite to form the more 
stable products, GSH and thiosulfate (Eq. 4.1) would be thermodynamically favored. It is 
therefore surprising that neither BpPRF nor TSTD1 show detectable sulfur transfer activity in the 
direction shown in Eq. 4.1 and suggests that one of the products (i.e. GSH or thiosulfate) might 
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be inhibitory. Hence, as the product builds up after a few turnovers and inhibits the reaction, it 
precludes product formation under multiple turnover conditions.  
To address this possibility, sulfur transfer reactions under single turnover conditions should be 
performed. If product formation is seen under these conditions, the inhibitory compound can be 
readily identified by performing the same reaction under single turnover conditions but with an 
excess of either GSH or thiosulfate. Additionally, this study should be expanded to TSTD1 to 
determine if a similar mechanism of product inhibition also underlies the apparent irreversibility 
of its sulfur transfer reaction. Studies on the TSTD1 and human rhodanese with GSH and 
thiosulfate as substrates (Eq. 4.1) revealed that they displayed substrate inhibition with 
thiosulfate, albeit at high millimolar concentrations (5-7). These observations suggest that 
thiosulfate might be a potential inhibitor for the sulfur transfer reaction in the reverse direction 
(Eq. 4.2). 
 Another future direction would be to examine the function of the N-terminal human 
rhodanese domain. Although catalytically inactive, the exact function of this domain is unknown. 
It has been proposed that the N-terminal domain is important for enzyme stability and/or it may 
be involved in allosteric regulation (8,9). As two examples of single domain sulfur transferases, 
the BpPRF rhodanese domain and TSTD1, do not display sulfur transfer activity towards GSSH 
and sulfite, it is possible that the catalytic rhodanese domain has an inherent auto-inhibitory 
activity, which is alleviated by the presence of the non-catalytic domain. To investigate this 
possibility, I propose isolation and characterization of the catalytic rhodanese domain to 
determine whether the absence of the non-catalytic domain affects the kinetics of the sulfur 
transfer reactions and, specifically, inhibits the reaction depicted by Eq. 4.1. Such a study would 
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provide insight into the function of the non-catalytic domain in rhodanese and aid in our 
understanding of how its activity is regulated.  
A future subject of investigation is the nature of the interactions between the PDO and rhodanese 
domain of the BpPRF. Kinetic analysis showed that mutagenesis of the rhodanese active site 
cysteine to serine decreases the PDO kcat/Km(GSSH) 146-fold, suggesting that the domains interact. 
Attempts at modeling a potential interaction interface between the two active sites did not 
provide any obvious clues into how these sites interact as the linker does not appear to be long 
enough to bridge the distance between the sites and surface electrostatics do not appear to be 
favorable. As crystallography only provides a snapshot of the enzyme, it is possible that the 
domains do interact directly and the conditions for capturing a “closed” conformation of the 
enzyme need to be determined. The wild-type enzyme was co-crystallized in the presence of 
thiosulfate resulting in the observed “open” conformation. The C314S enzyme, while in a 
different space group, crystallized in the same “open” conformation. It is possible that co-
crystallization in the presence of thiosulfate and GSH might result in a conformational change 
since GSH should mimic the binding interactions of the GSSH substrate. Another solution is to 
co-crystallize the enzyme under anaerobic conditions in the presence of the GSSH substrate, 
although the problem with this approach is the inherent instability of GSSH. Tyr196 is located in 
the PDO domain active site and participates in a hydrogen bond interaction with GSH. It would 
be worth exploring if Tyr196 supports fluorescence quenching studies for monitoring 
conformational changes in the presence of GSH or other substrates that could report on the 
putative “open” and “closed” conformational states of the enzyme.  
Modeling for the potential interaction interface between the PDO and rhodanese domains 
in a monomer suggests that the linker region may not be long enough and would have to undergo 
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an ~90° rotation and fold up towards the PDO active site. To investigate a possible interaction 
between the two domains, the length of the linker can be altered. A longer linker would provide 
increased range of movement while a shorter linker would preclude inter-domain interactions. 
The effects of these changes on the oligomeric state of the enzyme and the PDO and 
sulfurtransferase activities should be monitored. However, if the domains act independently of 
one another, the length of the linker might not have an effect on the activity of the enzyme. 
 Another possibility to be examined is if BpPRF forms a transient dimer during turnover 
conditions that brings the two active sites in proximity of each other. In this model, the enzyme 
does not adopt a closed conformation, but rather, the oligomeric state changes during catalysis. 
BpPRF crystallized with two-copies in the unit cell, which were arranged in a head-to-tail 
manner with the rhodanese domain of one monomer adjacent to the PDO domain of the second 





Figure 4.1 Orientation of BpPRF in the crystallographic unit cell. Two copies of BpPRF 
were observed in the unit cell. A, The BpPRF monomers crystalized in a head-to-tail orientation 
with the rhodanese domain (red for chain A, dark red for chain B) of one monomer adjacent to 
the PDO domain (blue for chain A, dark blue for chain B) of the other monomer. Iron atoms are 
shown as orange spheres. B, Surface representation of the two copies of BpPRF in the 
crystallographic unit cell. Chain A is shown in pink, and chain B is shown in blue. The iron 
atoms are represented as orange spheres. The PDO domain of chain A is proximal to the active 
site cysteine C314 of chain B, blocking solvent access. The top portion of the PDO active site 
groove run directly into the rhodanese domain on the adjacent chain, but does not connect to the 
active site cysteine. 
 
 In this head-to-tail arrangement of the BpPRF monomers a surface groove runs from the 
PDO active site to the rhodanese domain of the adjacent monomer but blocks access to the 
rhodanese active site cysteine (Fig. 4.1B). It is not currently known if this is a functionally 
relevant interaction between monomers or an artifact of crystal packing.  While transient dimer 
formation cannot be ruled out it would be appear to be entropically costly for monomers to come 
together during each catalytic cycle if the dimer is not stabilized by some ligand. Potential 
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experiments for investigation of a transient or stabilized dimer would involve size exclusion 
chromatography with multi-angle static light scattering (SEC-MALS) studies in the presence of 
GSH, sulfite or thiosulfate.  
 The BpPRF rhodanese domain contains an N-terminal -hairpin extension that is 
structurally unique to this rhodanese domain. A potential future direction of study is to determine 
the role of this unique structural feature. A possible approach is to identify key residues involved 
in stabilization of the -hairpin by mutagenesis and to disrupt the structure in both the stand-
alone rhodanese domain and the full length BpPRF. Characterization of the activities and 
stability of the -hairpin mutants will shed light on the functional role of this feature. Based on 
the BpPRF structures, we propose that two residues would be good starting points for 
mutagenesis: Ser249 and Thr247, which participate in hydrogen bonds and stabilize the structure 
(Fig. 4.2A). 
 
Figure 4.2. Structural investigation of the -hairpin extension in the BpPRF rhodanese 
domain. A, The -hairpin secondary structure is stabilized by several hydrogen bond 
interactions, notably those between the functional group of Ser249 and the backbone amides of 
Gly252 and Ile253 and the backbone carbonyl of Ile253. Additional hydrogen bonds stabilizing 
the -hairpin are between the functional group of Thr247 and the backbone amide and carbonyl 
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groups of Glu254. B, The two cysteine residues in the rhodanese domain are Cys314, the active 
site cysteine, and Cys248 which is located in the -hairpin extension region. Cys248 is exposed 
to the surface of the enzyme and its functional group does not participate in hydrogen bonding 
interactions with other residues in the rhodanese domain.  
 
 The hydroxyl group of Ser249 participates in hydrogen bonds with the backbone amide group of 
Gly252 and the backbone amide and carbonyl groups of Ile253. The hydroxyl group of second 
key residue Thr247, participates in hydrogen bonds with the backbone carbonyl and nitrogen in 
the amide group of Glu254 on the adjacent strand.  
 Additionally, another key residue of interest in the -hairpin loop is Cys248, which is 
surface exposed (Fig. 4.3B). As several BpPRF substrates (GSSH and thiosulfate) are reactive 
towards cysteine, modification of Cys248 might play a regulatory role. Future study of the 
functional consequences of mutating this cysteine will provide insights into the possible role of 
the -hairpin extension in BpPRF. 
 One concern with the current study of the BpPRF protein is that 40% of the wild-type 
enzyme as isolated, does not have iron bound. However, the crystallographic data suggests the 
enzyme is mostly if not completely loaded with iron. One possible explanation is that the only 
the holo-form of the enzyme is crystallized. While the colorimetric method used to quantify iron 
content is reliable with errors less than 5%, the Bradford assay used to determine protein 
concentration used bovine serum albumin as a standard, which could have led to inaccuracies in 
protein concentration determination and therefore to the iron to protein stoichiometry. To address 
the issue of whether the iron stoichiometry has been properly determined, amino acid analysis 
should be performed to determine the exact concentration of the BpPRF.  
Preliminary studies of spectral changes observed with the ferric form of the BpPRF in the 
presence of Na2S indicated that Na2S binds with moderate affinity and leads to hydrodisulfide 
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(HSSH) production under anaerobic conditions. This result suggests a potentially novel role for a 
non-heme iron protein in polysulfide production. It remains to be seen whether BpPRF can 
oxidize H2S under aerobic conditions to thiosulfate as reported for the heme proteins myoglobin 
and hemoglobin (10,11). If thiosulfate formation is supported by ferric PDO, it would help 
explain why elevated thiosulfate formation is seen in EE patients with mutations that lower the 
iron redox potential, which would favor the ferric oxidation state.   
 Finally, a broader question to be addressed in future studies is the function of PRF in 
bacteria. Our bioinformatics analysis suggests a potential role for the BpPRF in a sulfur 
assimilation pathway, likely from thiosulfate, for eventual production of cysteine. Limited 
analysis of the distribution of PRF proteins performed by our laboratory (unpublished results) 
and others (6,12) reveals that PRF proteins are broadly distributed across both gram positive and 
gram negative bacteria. Future studies should include a phylogenetic analysis to better 
understand the distribution of PRF proteins in bacteria. Such a study would provide insights into 
the function of PRFs in bacterial species that are pathogenic, or occupy specialized environments 
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